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ABSTRACT 
 
Diabetes education centres (DECs) provide patients with self-management skills 
to control diabetes and manage complications. To evaluate the effect of DEC attendance 
on prescriptions for diabetes treatments, prescriptions for cardiovascular risk reduction, 
and visits for retinopathy screening, a population based cohort study of residents of 
Ontario, Canada with diagnosed diabetes aged ≥65 years was performed using 
administrative databases. DEC attendance was identified using a registry of visits to all 
DECs in the province in 2006. Demographic and clinical confounders and pre-index 
utilization were used to adjust the logistic regression and also to construct a propensity 
score matched cohort.  Patients attending DECs had greater filling of prescriptions for 
statins than non-attendees in both analyses. DEC attendance was also associated with 
greater drug dispensation of glucose lowering medications, glucose monitoring strips and 
ACE inhibitors/ARBs, and visits to ophthalmology/optometry in both analyses. Diabetes 
self-management education at DECs is associated with better quality of care in the elderly 
in Ontario.  
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Chapter 1: Introduction 
1.1  Diabetes Burden and Prevalence 
Diabetes mellitus is a metabolic disease of hyperglycemia from defective insulin 
secretion, or action or both (Goldenberg et al., 2013). The long-term effects of this 
hyperglycemia are associated with the damage, dysfunction and failure of many organs 
including the kidneys, eyes, nerves, heart and blood vessels. Diabetes is classified into 
various types, the most common of which are type 1 and type 2. Type 1 diabetes is a 
result of pancreatic beta cell destruction from autoimmune or idiopathic process, leading 
to a lack of insulin secretion and susceptibility to ketoacidosis. Type 2 diabetes is mainly 
a problem of insulin resistance with relative insulin deficiency. Type 2 diabetes is more 
common than type 1 diabetes and comprises the majority of the diabetes population 
greater than 65 years of age. 
The prevalence of diabetes is increasing in Ontario, with the age-adjusted and sex-
adjusted diabetes prevalence increasing by 69%, from 5.2% in 1995 to 8.8% in 2005 
(Lipscombe et al., 2007). The prevalence of diabetes in adults greater than 50 years of age 
increased from 10.6% in 1995 to 17.1% in 2005, a prevalence rate increase of 62.8%. The 
prevalence of diabetes is 20% in women and 25% in men in the over 65 population in 
Ontario (Creatore et al., 2010). The cost of diabetes in Ontario is estimated at $4.9 billion 
in 2010 and expected to increase to over $6.9 billion by 2020 (Canadian Diabetes 
Association, 2009). As the prevalence and cost of diabetes increases in Ontario, the need 
to provide quality care through interventions such as diabetes self-management education 
(DSME) also increases. 
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1.2 Diabetes Education 
Management of diabetes, as in many chronic diseases such as asthma and 
rheumatoid arthritis, is dependent on the responsibility patients take in their own care 
(Newman et al., 2004). Patient involvement in the management of their care is termed 
self-management and includes the patients’ ability to manage the symptoms, treatment, 
physical and psychosocial effects and lifestyle changes essential to living with a chronic 
condition. For self-management to be effective it must include not only the ability to 
monitor ones condition and follow the treatment guidelines but to institute the 
psychological and social changes of living with a chronic illness to manage the effect on 
their lives. 
 The chronic disease self-management program, a community based patient self-
management education course involves three principal assumptions: different chronic 
diseases have similar self-management problems and disease-related responsibilities; 
patients can take responsibility for the daily management of their disease; and patients 
practicing self-management will have improved health status (Lorig et al., 1999). This 
model has been shown to increase healthful behaviors and maintain or improve health 
status and decrease rates of hospitalization in a heterogeneous group of diseases. 
Diabetes education provides patients with self-management skills necessary for 
management of diabetes such as diet and lifestyle changes, medication compliance, and 
self-monitoring of blood glucose (SMBG) (Ismail et al., 2004). The self-care 
responsibilities for optimum control include modification of lifestyle with diet, exercise, 
and weight loss, SMBG, foot care, and the administration of oral medications and insulin 
injections.  The objectives of DSME are to increase individual’s involvement, confidence 
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and motivation for control of their diabetes. Diabetes education for self-management is a 
fundamental component of diabetes care and most beneficial when working in 
conjunction with the healthcare team (Jones et al., 2013). It can be individualized to 
patient’s metabolic stability, treatment recommendations, readiness for change, learning 
style, ability, resources and motivation. It incorporates the physical, psychological and 
social management of living with a chronic illness. It uses didactic and non-didactic 
education sessions along with social, behavioral and psychological interventions.  
1.2.1 Meta-analyses of diabetes education 
Several trials have been published examining the effect of DSME on clinical 
outcomes including glycemic control, body weight, blood pressure, lipids, and 
requirement for blood glucose lowering medications (Norris et al., 2001). As most trials 
use glycemic control as a primary outcome, this outcome of diabetes education has been 
examined in meta-analyses. 
A meta-analysis of 21 randomized control trials (RCTs) published between 1990 
and 2000 examined 28 diabetes educational interventions on glycemic control (Ellis et al., 
2004). The trials included a total of 2439 participants with the trial size ranging from 23 
to 320. They included a heterogeneous group of interventions including didactic teaching, 
dictated goal setting, goal setting negotiated teaching method, situation problem solving, 
cognitive reframing interventions and other techniques with some studies incorporating 
more than one teaching method. The content included various combinations of 
information on diet, exercise, SMBG, basic diabetes knowledge, medication adherence, 
and psychosocial topics. The duration and number of interventions ranged from 1 month 
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to 1 year and 1 to 36 visits. The time period to the first post intervention glycated 
hemoglobin (A1C) ranged from 3 to 15 months with a net decrease in A1C of -0.320% 
(95% confidence interval (CI) -0.571%, -0.069%) using the fixed effects meta-analysis 
(test for heterogeneity Q=14, degrees of freedom (d.f.)=19, p=0.78). The net A1C 
decrease of trials with a 3 and 12 month follow up were not significant, but those with a 6 
month follow up had a significant net A1C decrease of -0.486% (95% CI -0.923%, -
0.049%). There was also a significant improvement in A1C in the control group from 
baseline at -0.66% (95% CI -1.054, -0.265) suggesting beyond standard of care some 
“control groups” also received education and increased visits. 
The random effects meta-analysis of glycemic change from baseline showed a 
drop in A1C of -1.136% (95% CI -1.481% to -0.790%) at the end of time period 1 (Q= 
132, d.f. 27, p<0.001). The change was also statistically significant at the end of 3, 6 and 
12 months with change in baseline A1C -1.238% (95% CI -1.665% to -0.811%), -0.892% 
(95% CI -1.428% to -0.356%) and -1.544% (95% CI -2.26% to -0.828%) respectively. 
Face to face interventions, using a cognitive reframing teaching model or that included 
content on exercise had a larger effect on decrease in A1C.  
A meta-analysis also including earlier studies published between 1980 and 1999 
involving health education in diabetes mellitus with glycemic control as a primary 
outcome incorporated 31 studies containing a total of 4263 patients (Norris et al., 2002). 
At the end of the intervention the A1C was decreased by 0.76% (95% CI 0.34 – 1.18%) 
more in the intervention group compared to the control group. At 1-3 months of follow up 
the A1C was a 0.26% (95% CI 0.21-0.73%) less in the intervention group than the control 
group and 0.26% (95% CI 0.05-0.48%) less in the intervention group than the control 
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group at >4 months of follow up. The meta-regression using the change in A1C as the 
dependent variable showed only total contact time was significant. Each additional hour 
of DSME reduced A1C by 0.04% (95% CI 0.01%-0.08%).  
A more recent meta-analysis of DSME by Minet et al., (2010) included 47 studies 
published up until 2007, with its earliest included study published in 1988, involving a 
total of 7677 participants. Eighteen studies used behavioral psychosocial techniques 
which included cognitive, behavioral and motivational approaches or psychology 
centered counseling in the intervention and 29 studies used educational techniques which 
used a didactic-oriented intervention focused on knowledge acquisition. Studies included 
individual and group sessions. The pooled mean difference in A1C between patients 
assigned to self-care management intervention was 0.36% (95% CI 0.21-0.51) compared 
to the control group by a random-effects model. The chi-squared for heterogeneity was 
significant (p<0.001). The pooled estimate with a fixed-effects model was similar at 
0.30% (95% CI 0.237-0.367). The factors which may influence the effect size of A1C 
change were studied by meta-regressions. The univariate meta-regression found a greater 
reduction in A1C in studies with a follow up period ≤ 12 months (effect size 0.49%, 
p=0.017). Those studies with a sample size ≤ 99 had a greater reduction in A1C (effect 
size 0.42%, p=0.007) compared to studies with a sample size >99. The difference in A1C 
reduction in studies using education techniques compared to behavioural psychosocial 
techniques and length of intervention were not significant. 
These meta-analyses showed a decrease in A1C with diabetes education 
intervention. However, the degree of decrease varied between the meta-analyses and at 
different time points within them. Part of this difference may be due to the different time 
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periods over which the results were included or a difference in the regression models 
used. Ellis et al., (2004) found the effect on A1C to be related to face to face 
interventions, using a cognitive reframing teaching model or that included content on 
exercise while Norris et al., (2002) found the effect on A1C to be related to only the total 
contact time and Minet et al., (2010) found the effect on A1C to be related to shorter 
follow up period after the intervention and small sample size. 
1.2.2  Individual diabetes education 
Individual diabetes education was examined in a meta-analysis by Duke et al., 
(2009) which included RCTs and controlled clinical trials that had at least a 6 month 
follow up period published until 2007. Individual education was compared to usual care 
in 7 studies. The 3 studies that assessed A1C at 6-9 months, included 295 participants, 
showed a trend toward decrease in A1C but this did not reach significance. The 4 studies 
involving 632 patients that examined A1C at 12 to 18 months found no significant change 
in glycemic control. There was a significant benefit to individual education on glycemic 
control in a sub analysis of 3 studies involving participants with a mean baseline A1C of 
>8% with a decrease of -0.3% (95% CI -0.5 to -0.1%, p=0.007). The 2 studies that 
compared individual education to group education found no significant difference in A1C 
at 12 to 18 months. There was no significant difference in body mass index (BMI), and 
blood pressure between the care types. In this meta-analysis individual care is as effective 
as group care and usual care for effect on A1C. 
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1.2.3  Group based diabetes education 
The effect of group-based diabetes education on clinical and lifestyle outcomes 
has been assessed in a meta-analysis by Deakin et al. (2005). It included 11 RCTs and 
control clinical trials of 1532 participants of group education with groups of at least 6 
participants compared to routine care, waiting list control or no intervention with follow 
up periods of at least 6 months. The meta-analysis of 3 studies with low heterogeneity 
(I
2
= 36.7%) shows group based diabetes education reduced A1C at 4 to 6 months by 1.4% 
(95% CI 0.8-1.9%, p<0.00001) compared to the control groups. This decrease was also 
seen at 12 to 14 months with a reduction of 0.8% (95% CI 0.7-1.0%; p<0.00001) in the 7 
studies with low heterogeneity (I
2
=18%) and at 2 years with a reduction of 1.0% (95% CI 
0.5 to 1.4%, p<0.0001) in the 2 studies that examined it (I
2
=0%). Due to heterogeneity 
between studies, fasting blood glucose results could only be combined between 4 studies 
at 1 year with a reduction of 1.2 mmol/L (95% CI 0.7-1.6, p<0.0001) in favour of group 
education. Group education had a positive effect on body weight but no effect BMI at 12-
14 months in 4 studies with a 1.6 kg (95% CI 0.3-3.0, p=0.02) weight loss in those who 
received group education. There was a reduction in systolic blood pressure at 4-6 months 
(5 mm Hg, 95% CI 1-10, p=0.01) but the difference was not significant at 12 months. No 
difference in lipid profiles was found between groups at any time point. There was a 
reduction in the need for diabetes medications in those receiving group education with an 
odds ratio (OR) of 11.8 (95% CI 5.5-26.9, p<0.00001). This meta-analysis shows positive 
effects of group education compared to usual care on glycemic control, body weight, 
blood pressure and use of diabetes medications. 
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 A recent meta-analysis by Steinsbekk et al. (2012) examined group based DSME 
compared to routine treatment. It included 21 RCTs from 1988-2007 in 26 publications 
with a total of 2833 participants. A1C was reduced by – 0.44% (95% CI -0.69 to -0.19%, 
p= 0.0006, I
2
 =56%, 13 studies) at 6 months with group based DSME. At 12 months A1C 
was reduced by -0.46% (95% CI -0.74 to -0.18%, p=0.001, I
2
= 65%, 11 studies). 
However, when 2 studies were removed due to the outlying results contributing to the 
high heterogeneity the 9 remaining studies showed a reduction in A1C of -0.50% (95% 
CI -0.73 to -0. 27%, p<0.0001, I
2
=33%). In the 3 studies that followed patients to 2 years 
there was a -0.87% (95% CI -1.25 to -0.49%, p<0.0001, I
2
=0) reduction in A1C. Sub 
group analysis suggested that group DSME delivered by a single educator, over more 
than 12 hours in less than 10 months in 6 to 10 sessions gave the best improvement in 
glycemic control.  
Group based diabetes education was found to reduce A1C in these meta-analyses 
with positive effects also seen on body weight, blood pressure and use of diabetes 
medications. Steinsbekk et al. (2012) found that group DSME delivered by a single 
educator, over more than 12 hours in less than 10 months in 6 to 10 sessions, gave the 
best improvement in glycemic control. 
1.2.4  Effect of diabetes education on cardiovascular risk factors 
The Steinbekk et al. (2012) meta-analysis also examined various lifestyle 
outcomes and cardiac risk factors. There was a significant improvement in diabetes 
knowledge and self-management skills with group DSME but the heterogeneity was high. 
Self-efficacy and empowerment was significantly increased with a standard mean 
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difference of 0.28 (95% CI 0.06 to 0.50, p=0.012, I
2
=0). Treatment satisfaction was 
increased at 6 and 12 months with a standard difference in the mean of 0.65 (95% CI 0.44 
to 0.85, p<0.0001, I
2
=0, 2 studies) and 0.39 (95% CI 0.21 to 0.57, p<0.0001, I
2
=0.0, 3 
studies). However, there was no difference in quality of life. Weight was significantly 
improved at 12 months but not at 6 months. There was no significant difference in 
mortality, BMI, blood pressure and lipid profile.  
A systematic review of diabetes education trials published between 1980 and 1999 
found several studies that examined cardiovascular risk factors (Norris et al., 2001). 
Thirteen studies had a positive effect on weight loss, while many did not. The studies 
with a positive effect generally involved regular contacts or reinforcement sessions or a 
short follow up period with those studies of ≥6 months follow up having no significant 
difference between groups. Some studies found an improvement in total cholesterol, low 
density lipoprotein (LDL) and high density lipoprotein (HDL) cholesterol with self-
management training where others found an initial positive result but no significant 
difference at the final follow up. The individualized and repetitive interventions were 
more likely to improve lipid levels where as didactic interventions did not improve lipid 
profiles. 
1.2.5 Recent trials of diabetes education  
Some more recent studies on DSME have been published that were not included 
in the earlier meta-analysis and systematic reviews. They include DESMOND (Diabetes 
Education and Self-management for Ongoing and Newly Diagnosed type 2) from the 
United Kingdom (Davies et al., 2008) and Rethink Organization to iMprove Education 
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and Outcomes (ROMEO) from Italy (Trento et al., 2010) as well as studies from 
Germany, the Netherlands and Malaysia. These studies instituted a variety of DSME 
interventions as outlined and examined the effect on glycemic control as well as 
cardiovascular risk factors. 
DESMOND, a multicentre cluster RCT of 824 patients at 207 general practices in 
13 primary care sites in United Kingdom compared a structured education program 
delivered by 2 healthcare professional educators to usual care (Davies et al., 2008). The 
program consisted of 6 hours delivered in 1 day or 2 half days using a non-didactic 
approach to present the curriculum focused on lifestyle factors as part of self-
management.  DESMOND showed no difference in the primary outcome of A1C at 12 
months with a non-significant decrease in both group education and usual care. Weight 
loss was greater in the group education setting at −2.98 kg (95% CI −3.54 to −2.41 kg) 
compared with −1.86 kg (95% CI −2.44 to −1.28 kg), (p=0.027) at 12 months. There was 
no difference in cholesterol profile, blood pressure or waist circumference between 
groups. The OR for using an oral hypoglycaemic agent at month 12 of the trial was 0.79 
(Gillett et al., 2010). The OR of using a statin at month 12 of the trial was 0.99. The OR 
of antihypertensive use was 1.18 (95% CI 0.71 to 1.98). Smoking was higher in the 
control group compared to the intervention group at 12 months with an OR of 3.56 (95% 
CI 1.11 to 11.45, p=0.033) (Davies et al., 2008). The intervention group had a 
significantly improved understanding of diabetes with a greater improvement in the 
illness belief scores and lower depression score than the control group. The estimated 
mean incremental lifetime cost per person receiving the DESMOND intervention was 
£209 (95% CI −£704 to £1137) (Gillett et al., 2010). The incremental gain in quality 
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adjusted life years (QALY) per person is 0.0392 (95% CI −0.0813-0.1786) with a mean 
incremental cost per QALY of £5387. Using simulated long term effect there is 66% 
likelihood that the DESMOND intervention is cost effective.  
A RCT of patients with non-insulin dependent type 2 diabetes managed by 
systemic group education or usual care of individual consultations and education was 
performed in 112 patients in Italy (Trento et al., 2001) with follow up at two, four (Trento 
et al., 2002) and five years (Trento et al., 2004). At 2 years the A1C had increased in the 
control group from 7.4% ± 1.4% to 8.3% ± 1.8% but remained unchanged in the 
intervention group at 7.4% ± 1.4% to 7.5% ± 1.4% (p<0.002). HDL cholesterol was 
increased in group patients but not control patients. There was no significant difference in 
fasting blood glucose, total cholesterol, triglycerides, creatinine, albuminuria, body 
weight, BMI, foot ulcers or diabetic retinopathy between groups. Knowledge of diabetes, 
health behaviors and quality of life were also significantly improved with group care.  At 
four years, A1C remained stable in the group patients from 7.4% ± 1.4% at baseline to 7.0 
± 1.1% and continued to rise in the individual care patients from 7.4% ± 1.4% at baseline 
to 8.6% ± 2.1% (p<0.001) (Trento et al., 2002). Body weight and BMI decreased and 
HDL increased in the group patients over 4 years but there was no significant difference 
in the individual care patients. The knowledge of diabetes, health behaviours and quality 
of life improved in the group care patients and declined in the individual care group. 
Diabetes medication use was decreased in the group care patients compared to the 
individual care patients suggesting improved compliance to lifestyle modification with 
diabetes education leading to better control of diabetes (Trento et al., 2002). At five years 
follow up A1C in the group patients continued to remain stable at 7.3% ± 1.0% compared 
  
12 
 
to an increase in control patients to 9.0% ± 1.6% (p<0.001) (Trento et al., 2004). At five 
years knowledge of diabetes, problem solving ability, and quality of life continued to 
improve in the group patients and decrease in the control patients. Body weight but not 
BMI was decreased from baseline in the group patients at five years. The group patients 
maintained better long-term glycemic control than the individual care patients suggesting 
group care may be more effective.  
The ROMEO trial is a multicenter trial performed to examine if the results of 
group care model of diabetes lifestyle intervention from a single center described by 
Trento et al. (2004) was transferable to other clinics (Trento et al., 2010). It was a 4 year 
RCT of group care vs. routine individual care of 815 patients with non-insulin dependent 
type 2 diabetes performed in 13 diabetes clinics in Italy. At 4 years the group patients had 
a lower A1C at 7.3% ± 0.9% compared to 8.8% ± 1.2% in the routine care patients 
(p<0.001) and the OR of having an A1C ≤ 7.0% was 29.4 (95% CI 14.2-60.8, p<0.001) in 
favour of group care. Group care subjects also had significantly higher HDL cholesterol, 
lower fasting glucose, LDL cholesterol, triglycerides, blood pressure, body weight, BMI, 
and creatinine compared to control subjects. At the end of the study, group care patients 
were more likely to have reached all treatment targets whereas fewer control patients had 
an A1C ≤ 7.0% at study end compared to at the initiation and there was no change in the 
proportion reaching the other treatment targets. Health behaviours, quality of life and 
diabetes knowledge were significantly improved for group care patients compared to no 
change in health behaviours and a worsening of quality of life and knowledge seen in 
control patients. Prescriptions for hypoglycemic, antihypertensive and lipid lowering 
medications were similar between groups suggesting healthier behaviors with group care. 
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ROMEO demonstrates that continuing interactive patient-centered education by group 
care significantly improves outcomes.  
A prospective RCT of three education programs for 181 type 2 diabetes patients in 
Germany compared a didactic-oriented training program, a self-management-oriented 
program delivered in a group setting and a more individualized self-management program 
where half the sessions were conducted in an individual setting (Kulzer et al., 2007). The 
didactic program focused on the knowledge, skills and information about the treatment of 
diabetes in four 90 minute lessons in a group setting in a program which has been 
previously studied and used since the late 1980’s. The self-management program focused 
on the emotional, cognitive and motivational process of behavior change and was 
delivered twelve 90 minute lesions in a group setting. The final program had the same 
content of the second program but was delivered in 6 group sessions and 6 individual 
sessions. The group based self-management program had a 0.7% fall in A1C that was 
sustained at 12 months after completion of the intervention (p=0.013). There was no 
change in A1C in the didactic program. The individualized program had a drop in A1C at 
3 months but this was not maintained at 12 months. There were also benefits seen for 
BMI, fasting blood glucose, psychological variables and exercise in the group self-
management program.  
A RCT of 54 patients in the Netherlands with type 2 diabetes treated with 
maximum oral agents with an A1C≥7.0% was performed to examine the long term 
outcome of DSME (Goudswaard et al., 2004). Patients were randomly assigned to 6 
month education program by diabetes nurse or usual care by their general practitioner 
with a primary outcome of the proportion of patients with an A1C<7% 1 year after the 
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end of the intervention. An A1C < 7% was achieved by 60% of the patients in the 
diabetes education group and by 17% of the patients in the usual care group (OR 6.6; 
95% CI 1.8-24.5, p=0.004). The mean A1C in the diabetic education group fell from 
8.2% ± 1.1% to 7.2% ± 1.3% and in the usual care group from 8.8% ± 1.5% to 8.4% ± 
1.7%. The difference in the mean change in A1C was not statistically significant at 0.2% 
(95% CI -0.7% to +0.4%) in favor of the diabetes education group when adjusted for 
baseline values. 
A RCT of a 12 week DSME program in Malaysia consisting of two in-person 
individual education sessions and one telephone follow up was compared to usual care in 
164 patients (Tan et al., 2011). At the end of the 12 week intervention there was a 
significant reduction in total daily calorie intake and increase in activity in the 
intervention group based on self-reported food diaries and questionnaires. Based on self-
reported questionnaires, 91% (95% CI 89-94%) of the intervention group were adherent 
to prescribed medications (defined as consuming ≥ 90% of prescribed medications in the 
previous week) compared to 84% (95% CI 82-87%) (p=0.008) of the usual care group at 
week 12. There was also more SMBG in the intervention group at the end of 12 weeks 
compared to no change in the control group based on the count of returned glucose test 
strips and self-monitoring diaries. At 12 weeks the A1C was lower in the intervention 
group at 8.75% ± 1.75% compared to 9.67% ± 2.01% in the control group (p<0.001). The 
A1C difference at 12 weeks persisted after adjusting for medication adherence, SMBG 
frequency and body weight.  
These more recent studies of DSME had variable effects on glycemic control and 
other outcomes. Trento et al. (2001, 2002, 2004) had shown improvements in glycemic 
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control and other outcomes with patient centered group diabetes education that were 
confirmed in the ROMEO trial (Trento et al., 2010).  DESMOND, did not find a 
significant difference in the decrease in A1C between groups (Davies et al., 2008). It did 
find a significant benefit with the structured diabetes education program with weight loss 
and smoking cessation. The smaller studies did show a significant difference in A1C 
however one study had only a 12 week follow up. These studies also showed benefit in 
other outcomes such as BMI and other self-management behaviors. These recent studies 
together with the meta-analysis suggest a positive effect of DSME on various outcomes. 
1.2.6 Methodological issues with diabetes education trials 
There are many methodological issues with these trials examining diabetes 
education (Norris et al., 2001).  Descriptive information is frequently lacking in many 
trials, including details of the study population such as the type of diabetes, as well as 
details of interventions. The usual care of the control groups in each study varies and is 
not always defined. The study populations may not be representative of the target 
population due to selection, performance, and attrition bias (Juni et al., 2001).  Selection 
bias may exist when there are systemic differences in the control and intervention groups 
at baseline.  This possibility may only be excluded with randomization. The 
generalizability of the results may be limited by provider and patient selection simply due 
to their willingness to participate in a trial (participation bias). Differences in provider and 
patient behavior can also result from the Hawthorne effect, i.e. subjects that know they 
are part of a study behave differently due to this fact alone. These studies were often 
performed at tertiary care centres or university hospitals, which may differ from 
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community settings in the types of patients and the care they receive. Some studies 
limited enrollment to newly diagnosed patients with type 2 diabetes which limits the 
generalizability to the larger population with diabetes. Performance bias may result from 
differences in care provided to the control and intervention groups other than the 
intervention being evaluated. To prevent this there should be no evidence of 
contamination or co-intervention, including no additional contacts with researcher or 
providers for the intervention group compared with the control group or compared to 
routine care. Additional clinical resources, intensity of follow-up, and other factors 
related to a study can make all trial participants (regardless of randomization arm) 
different from the real world patients in clinical care. Attrition bias results from different 
rates of withdrawal from the study between groups. To avoid this, the attrition rates 
should generally be <20% of the total number and dropouts must resemble completers in 
baseline characteristics.  These numerous factors that make the study population different 
from the general population of real-world clinical care can threaten the external validity 
of the studies of DSME.  
In studies of diabetes education, the internal validity was threatened by a variety 
of factors. The assessors were often not blinded and it is impossible to blind the study 
subjects. There was a lack of information on the process of randomization and allocation 
concealment. There were high attrition rates in some studies and evidence of co-
interventions with some control groups being more frequently than standard of care and 
receiving some form of education. There was a potential for response-set bias where the 
intervention group self-reported dietary, exercise and glucose self-monitoring habits that 
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match the goals of the intervention rather than actual behavior. The instruments used to 
measure diabetes knowledge, self-care and dietary habits, have not been validated.  
The actual DSME intervention also takes many forms, including individual 
sessions, group sessions, didactic teaching and cognitive behaviour therapy. Many studies 
included fewer than 100 participants and few studies included a statistical power 
calculation. While these interventions may be efficacious in selected study populations 
under the supervision of study investigators, they may not be as effective in the general 
population where there is a wider variety of clinicians and patients.  There is little real 
world evidence of the effectiveness of diabetes education. 
1.3 Ontario Diabetes Education Centres  
A survey with linked health care administrative data of 781 patients with diabetes 
greater than 2 years duration in Ontario in 2003-2004 examined predictors of Diabetes 
Education Centre (DEC) attendance and quality of care indicators for effectiveness of 
DSME (Shah et al., 2009). Of the respondents, 30% had attended a DEC in 2002. 
Predictors of DEC attendance included recently diagnosed diabetes, receiving regular 
specialist care, receiving regular primary care visits and marital status. A propensity score 
model derived from demographics, health service utilization, diabetes clinical features, 
and other medical conditions was used to examine quality of care indicators such as 
capillary glucose testing, retinal screening examination, acute diabetes complications and 
continuity of primary care between the attendees and non-attendees. DEC attendees were 
more likely to receive retinal screening examination in the 2 years following than those 
who did not attend a DEC. There was no difference in the other quality of care indicators. 
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Attendance at DECs in Ontario has previously been shown to be associated with 
more glucose self-monitoring in attendees vs. non-attendees (86.2% vs. 53.5%, adjusted 
OR 6.45, 95% CI 5.61-7.42, p < 0.0001) in a cross-sectional study of a subset of the over 
65 population in Ontario (Millar et al., 2010). Anti-hypertensive medications (88.3% vs. 
83.0%, adjusted OR 1.30, 95% CI 1.12–1.51, p=0.0006) and lipid-lowering drugs (77.2% 
vs. 65.6%, adjusted OR 1.68, 95% CI 1.50–1.88, p <0.0001) were also used more by the 
DEC attendees. DEC attendees were also more likely to have an eye examination 
(adjusted OR 1.13, 95%CI 1.02–1.26, p=0.0229). This study showed an association 
between DEC attendance and objective evidence of better management of diabetes.    
A population based cohort study of all adults with diabetes who attended DECs in 
Ontario in 2006 examined DEC attendance by those with newly diagnosed diabetes 
(Cauch-Dudek et al., 2013). Only 20.6% of those with newly diagnosed diabetes attended 
a DEC within 6 months of diagnosis. Patients of older age, lower socioeconomic status 
and recent immigrants were less likely to attend. Mental health conditions and other 
medical comorbidities were also associated with not attending DECs suggesting those 
most in need of DSME are not receiving this resource.  
1.4 Diabetes guidelines 
 Many studies have shown the benefits of glycemic control, antihypertensive 
medications and cholesterol lowering medications in lowering morbidity and mortality in 
diabetes. The targets of the Canadian Diabetes Association Guidelines are based on this 
evidence (Cheng et al., 2013). The recommended glycemic target is an A1C of ≤7.0% to 
reduce microvascular complications and, in type 1 diabetes, macrovascular complications 
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(Imran et al., 2013). In Canada, males with diabetes greater than 45 years of age and 
females with diabetes greater than 50 years of age are considered to be at high risk for 
cardiovascular disease and should be considered for vascular protection (Stone et al., 
2013). This includes optimization of blood pressure to the target of <130/80 mmHg 
which often requires multiple antihypertensive agents, starting with angiotensin 
converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy, and 
lipid-lowering medication, primarily statins, to target an LDL cholesterol of ≤ 2.0 
mmol/L. All patients with type 2 diabetes and patients with type 1 diabetes greater than 
15 years of age should undergo screening for retinopathy every 1 to 2 years (Boyd et al., 
2013). The information and recommendations in the guidelines, based on the evidence for 
glycemic control, lipid and blood pressure management, complication screening and 
management as outlined below provide a basis for the goals of DSME.  
1.5 Benefits of glycemic control  
1.5.1 Type 1 diabetes 
The Diabetes Control and Complications Trial (DCCT) randomized 1441 patients 
with type 1 diabetes, to intensive (goal A1C<6.0%) or conventional therapy for a mean of 
6.5 years between 1983 and 1993 (DCCT group, 1993). At the end of the study the 
difference in A1C was 1.7% (7.4% in the intensive-treatment group vs. 9.1% in the 
conventional-treatment group, p<0.01). The intensive-treatment group had a 76% risk 
reduction (95% CI 62 to 85%, p<0.001) for the development of retinopathy
 
compared to 
conventional therapy. With intensive therapy there was also slowed progression of pre-
existing retinopathy with a 54% risk reduction (95% CI 39 to 66%, p<0.001). The risk 
reduction in the development of proliferative or severe non-proliferative
 
retinopathy was 
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47% (95% CI 14
 
to 67%, p=0.011). The absolute risk reduction in the development of 
severe nephropathy was 4.04% in the intensive group. The risk of microalbuminuria was 
reduced by 39% (95% CI 21 to 52%, p≤0.002) and albuminuria by 54% (95% CI 19 to 
74%, p<0.04) in the intensive group. The risk of clinical neuropathy at 5 years was also 
reduced by 60% (95% CI 38 to 74%, p≤0.002).   The absolute risk reduction in the 
development of clinical neuropathy in the primary prevention group was 7% (p=0.006) 
with intensive treatment and 9% in the secondary prevention cohort (p<0.001). During 
DCCT, there were fewer cardiovascular events in the intensive group but the young age 
of the cohort and small number events did not lead to a statistically significant difference. 
The DCCT showed that tight glycemic control with an A1C of 7.4% in the intensive 
treatment group is associated with a reduced risk of neuropathy, nephropathy and 
retinopathy in type 1 diabetes. 
Ninety-three percent (n=1397) of participants were followed until February 1, 
2005, during the observational Epidemiology of Diabetes Interventions and 
Complications (EDIC) study (Nathan et al., 2005). At the end of DCCT, the conventional 
group was advised to follow intensive control and the intensive group went back to 
regular clinical care.   At the end of the EDIC study period there was no difference 
between groups in A1C, 7.9% in the intensive group and 7.8% in the conventional group. 
The time to first to cardiovascular event became statistically significant during the follow 
up observational period, suggesting a lasting benefit of tight control as the 2 groups had 
no difference in A1C during this period (Nathan et al., 2005). The intensive arm had a 
42% risk reduction (95% CI 9-63%; p=0.02) compared to the control group at a mean 17 
years of follow up, 7 years after the study intervention was completed.  The event rates 
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for the first cardiovascular event were 0.38 and 0.80 per 100 patient-years in the intensive 
and control group respectively (p=0.007). The risk reduction for first occurrence of 
nonfatal myocardial infarction (MI), stroke, or death from cardiovascular disease was 
even greater at 57% (95% CI 12-79%; p=0.02). The effects on microvascular disease 
were also preserved in follow up (Writing team for DCCT/EDIC Research Group, 2002). 
EDIC demonstrated that early intensive glycemic control is associated with a reduction in 
both microvascular and macrovascular disease in patients with type 1 diabetes. 
1.5.2 Type 2 Diabetes 
The United Kingdom Prospective Diabetes Study (UKPDS) examined intensive 
glucose control to conventional therapy in newly diagnosed type 2 diabetes (UKPDS 33 
and 34, 1998). The participants were followed for an average of 10 years from 1977-
1997.  The average A1C was 7.0% in the intensive group vs. 7.9% in the control group in 
the sulfonylurea/insulin study (UKPDS 33, 1998) and A1C 7.4% vs. 8.0% in the 
metformin study (UKPDS 34, 1998). The relative risk of any diabetes-related end point 
was 0.88 (95% CI 0.79-0.99, p=0.029) in the intensive treatment group with sulfonylurea 
and insulin (UKPDS 33, 1998).  The relative risk of microvascular disease was 0.75 in the 
sulfonylurea/insulin arm (95% CI 0.60-0.93, p=0.0099).  This was mainly driven by the 
reduction in the need for retinal photocoagulation and cataract extraction. There was no 
difference in diabetes related death mortality, all-cause mortality or macrovascular 
disease. UKPDS showed that tight glycemic control with an A1C of 7% early in 
diagnosis of type 2 diabetes reduces the risk of microvascular disease. 
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78% of the participants in UKPDS agreed to enroll in post-trial monitoring and 
were followed for 10 more years, the predicted 50% mortality rate point (Holman et al., 
2008). The difference in A1C between groups was lost after the first year following the 
completion of the study intervention. At 10 years post study, there was a significant 
decrease in any diabetes related end point in the patients originally in the 
insulin/sulfonylurea group with a 9% relative risk reduction (p=0.04). Diabetes related 
death was reduced by 17% (p=0.01), death from any cause by 13% (p=0.007), MI by 15% 
(p=0.01), and microvascular disease by 24% (p=0.001). In the patients originally in the 
metformin treated group, the reduction in any diabetes related end point persisted at 10 
years post study with a relative risk reduction of 21% (p=0.01). The difference in diabetes 
related death, MI and all-cause mortality with metformin persisted at 10 years with 
relative risk reductions of 30% (p=0.01), 33% (p=0.005) and 27% (p=0.002) respectively. 
The intensive glycemic control early in type 2 diabetes continued to provide benefit in 
macrovascular and microvascular disease 10 years after cessation of the trial despite a 
loss of difference in A1C between groups suggesting a legacy effect of tight glucose 
control (Chalmers et al., 2008).   
ACCORD (Action to Control Cardiovascular Risk in Diabetes Study) randomized 
10,251 patients with a median A1C 8.1% and 10 year duration of type 2 diabetes to 
intensive glucose control with a target A1C of <6.0% or standard therapy (Gerstein et al., 
2008). An A1C of 6.4% was achieved in the intensive group compared to 7.5% in the 
control group. The primary outcome, a composite end point of nonfatal MI, stroke, or 
death from cardiovascular disease, had a hazard ratio (HR) of 0.90 (95% CI 0.78-1.04; 
p=0.16) when the trial was stopped at 3.5 years due to an increase in death in the 
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intervention group.  There was a 22% increase in mortality with a 35% increase in 
cardiovascular mortality with a HR of 1.22 for all-cause mortality (95% CI 1.01-1.46; 
p=0.04) and a HR of 1.35 for cardiovascular mortality (95% CI 1.04–1.76; p=0.02) with 
intensive treatment.  Hypoglycemia was significantly higher in the intensive group. Post 
hoc analysis of episodes of severe hypoglycaemia and differences in the use of drugs 
including rosiglitazone, weight change, and other factors could not explain the increased 
mortality with intensive therapy. ACCORD provides evidence that older patients with 
long standing type 2 diabetes may not benefit from tight glycemic control with an A1C 
<6%. 
ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation) randomized 11,140 patients with an 8 year 
mean duration of diabetes, a mean A1C 7.5%, and 32% had a history of macrovascular 
disease, to standard glucose control or intensive glucose control using gliclazide MR plus 
other drugs as required to achieve A1C ≤ 6.5% (Patel et al., 2008). During the 5 year 
study the groups obtained an average A1C 6.5% and 7.3% respectively. The occurrence 
of combined major macrovascular and microvascular events was reduced by intensive 
control with a HR of 0.90 (95% CI 0.82 to 0.98; p=0.01). Major microvascular events 
were also reduced by intensive control with a HR of 0.86 (95% CI 0.77 to 0.97; p=0.01). 
This was driven by a reduction in the incidence of nephropathy (HR 0.79; 95% CI 0.66 to 
0.93; p=0.006). ADVANCE demonstrated that an A1C of 6.5% in patients with type 2 
diabetes of 8 years duration is associated with a reduction in nephropathy but did not 
affect macrovascular disease and other microvascular disease. 
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Veteran’s Affairs Diabetes Trial (VADT) randomized 1791 military veterans with 
a 11.5 year duration of type 2 diabetes, 40% incidence of a prior cardiovascular event,  
and a baseline A1C 9.4% to intensive control with an A1C of <6% vs. standard control 
(Duckworth et al., 2009). They achieved an A1C of 6.9% in the intensive group vs. 8.4% 
in the standard group with a mean follow up of 5.6 years. There was no difference in the 
primary outcome of major cardiovascular events, in any component of the primary 
outcome, death from any cause, or microvascular complications.  
An A1C of <7% has been shown to reduce microvascular complications of type 1 
and type 2 diabetes in multiple trials (DCCT group, 1993; UKPDS 33, 1998; UKPDS 34, 
1998; Patel et al., 2008).  More intensive glucose control has not shown any significant 
reduction of cardiovascular disease compared to standard glycemic control during the 
randomized portion of the trials (DCCT group 1993; UKPDS 33, 1998; Gerstein et al., 
2008; Patel et al., 2008; Duckworth et al., 2009) despite the association of high A1C with 
cardiovascular disease. The post-trial follow-up periods of DCCT/EDIC and UKPDS did 
show a reduction in cardiovascular disease suggesting a legacy effect of early glycemic 
control (Nathan et al., 2005; Holman et al., 2008). 
1.6 Multifactorial intervention 
 STENO2 randomized 160 patients with type 2 diabetes and microalbuminuria to 
intensified, multifactorial intervention or conventional treatment in accordance with 
national guidelines on risk factors for cardiovascular disease in an open label parallel trial 
conducted in Denmark from 1993-2001 (Gaede et al., 2003). The intensive treatment 
consisted of stepwise implementation of behaviour modification and pharmacologic 
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therapy to target hyperglycemia to A1C <6.5%, hypertension, dyslipidemia, 
microalbuminuria, smoking cessation and secondary prevention of cardiovascular disease 
with aspirin. The A1C at the end of the study period was 9.0% ± 1.8% in the conventional 
group and 7.9% ± 1.2% (p <0.001) in the intensive group with about 15% obtaining the 
goal A1C <6.5%. The risk of cardiovascular disease was significantly reduced with 
intensive therapy with a HR of 0.47 (95% CI 0.24 to 0.73, p=0.008). Nephropathy (HR 
0.39; 95% CI 0.17 to 0.87), retinopathy (HR 0.42; 95% CI 0.21 to 0.86), and autonomic 
neuropathy (HR 0.37; 95% CI 0.18 to 0.79) were also reduced in the intensive 
intervention group. 
STENO2 patients were then followed for 5.5 years after the end of the study to a 
total of 13.3 years follow up (Gaede et al., 2008). By the end of the follow up period there 
was no difference in A1C between the groups.  The risk of death from any cause was 
decreased with intensive therapy (HR 0.54; 95% CI 0.32 to 0.89; p=0.02). Intensive 
therapy also lowered the risk of death from cardiovascular causes, cardiovascular events, 
and end-stage renal disease, and the need for retinal photocoagulation.  
STENO2, which achieved an A1C 7.9%  as well as targeting multiple risk factors,   
significantly lowered  the risk of cardiovascular disease (Gaede et al., 2003) with the 
effect preserved in post study follow up (Gaede et al., 2008). Nephropathy, retinopathy 
and autonomic neuropathy were also reduced in the intensive intervention group (Gaede 
et al., 2003) with a reduction in progression to end stage renal disease and need for retinal 
photocoagulation seen in the post study follow-up (Gaede et al., 2008). STENO2 program 
of behavioural modification and pharmacologic therapy to target a multiple risk factors 
requires a multidisciplinary approach that would include diabetes education to implement 
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the required teaching and behaviour modification to achieve outcomes that are not be 
achieved with glycemic control alone. 
1.7 Lipid management in Diabetes 
The Heart Protection Study (HPS) diabetes cohort of 5963 subjects showed 
treatment with 40 mg simvastatin daily resulted in a 27% reduction in cardiovascular 
events and a 25% reduction in stroke relative to placebo, which was similar to the cohort 
without diabetes (Collins et al., 2003). The Collaborative Atorvastatin Diabetes Study 
(CARDS) was conducted in people with type 2 diabetes with a mean baseline LDL of 3.1 
mmol/L without known vascular disease and at least 1 additional risk factor for 
cardiovascular disease (Colhoun et al., 2004). Treatment with atorvastatin 10 mg daily to 
a mean LDL of 2.0 mmol/L reduced the risk of first cardiovascular disease events by 37% 
and risk of stoke by 48%.  
The Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm 
(ASCOT-LLA) of 10,305 hypertensive patients with no history of coronary heart disease 
but at least three cardiovascular risk factors were randomly assigned to receive 10 mg 
atorvastatin or placebo for a mean follow up of 3.3 years (Server et al., 2005). The 
subgroup analysis of 2,532 patients with type 2 diabetes at the time of randomization 
showed similar benefit of atorvastatin as seen in the entire cohort. The atorvastatin group 
had 116 (9.2%) major cardiovascular events or procedures compared to 151 (11.9%) 
events in the placebo group (HR 0.77, 95% CI 0.61– 0.98; p=0.036). The number of 
events occurring in the diabetes subgroup was small and although there were less 
coronary events (HR 0.84, 95% CI 0.55–1.29; p=0.14) and strokes (HR0.67, 95% CI 
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0.41–1.09; p=0.66) in the atorvastatin group, the reductions were not statistically 
significant. 
The Treating to New Targets (TNT) trial included a diabetic subgroup of 1051 
subjects with stable coronary artery disease treated with atorvastatin 80 mg or 10 mg 
daily (Shepherd et al., 2006). Subjects treated with atorvastatin 80 mg daily that achieved 
a group mean LDL of 2.0 mmol/l had 25% fewer major cardiovascular events than those 
treated with atorvastatin 10 mg daily who achieved a mean LDL of 2.5 mmol/L 
(p=0.026). Atorvastatin 80 mg also reduced the rates of all cardiovascular and 
cerebrovascular events compared to atorvastatin 10 mg daily. The diabetes subgroup had 
an increased event rate for all primary and secondary efficacy outcomes compared to the 
overall study population. This reinforces the evidence that people with diabetes and 
coronary artery disease are at high risk of subsequent cardiovascular events. 
The evidence from HPS, CARDS, ASCOTT-LLA and TNT show the benefit of 
statin treatment for LDL cholesterol in patients with diabetes at risk for cardiovascular 
and cerebrovascular disease. This important risk factor for macrovascular disease is one 
of the topics addressed in diabetes education.  
1.8 Blood Pressure management 
 UKPDS showed that tight blood pressure control with a mean blood pressure of 
144/82 mm Hg over 8.4 years of follow up compared to 154/87 mm Hg in the 
conventional arm reduced the risk of microvascular disease stroke and deaths related to 
diabetes (Adler et al., 2000).  For every 10 mm Hg decrease in mean systolic blood 
pressure there was a 12% risk reduction in any complication related to diabetes (95% CI 
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10-14%, p<0.0001), a 15% risk reduction in deaths related to diabetes (95% CI 12-18%, 
p<0.0001), a 11% risk reduction in MI (95% CI 7-14%, p<0.0001, and a 13% risk 
reduction in microvascular complications (95% CI 10-16%, p<0.0001).   
The Hypertension Optimal Treatment (HOT) Study of 18 790 patients, aged 50-80 
years with hypertension and diastolic blood pressure between 100 mm Hg and 115 mm 
Hg,  assigned patients to 3 groups based on target diastolic blood pressure of ≤90 mm Hg, 
≤85 mm Hg and ≤80 mm Hg (Hansson et al., 1998).  In the diabetes subgroup there was a 
51% reduction in major cardiovascular events in the ≤80 mm Hg group compared with 
the ≤90 mm Hg group (p=0.005). 
The Appropriate Blood Pressure Control in Diabetes (ABCD) trial of 
normotensive patients with type 2 diabetes to intensive control of 10 mm Hg below the 
baseline diastolic blood pressure or moderate control with a diastolic blood pressure of 
80-89 mm Hg (Schrier et al., 2002). Over a period of 5.3 years the average blood pressure 
in the intensive group was 128±0.8/75±0.3 mm Hg compared to 137±0.7/81±0.3 mm Hg 
in the moderate group (p<0.0001). There was no difference in the primary end point of 
change in creatinine clearance (p=0.43). Fewer patients in the intensive group reached the 
secondary end points of progression from normoalbuminuria to microalbuminuria 
(p=0.012) and microalbuminuria to overt albuminuria (p=0.028). The intensive control 
group also has less progression of diabetic retinopathy (p=0.019) and a lower rate of 
strokes (p=0.03). 
The ADVANCE trial examined the effects of fixed combination of perindopril 
and indapamide compared to placebo on macrovascular and microvascular outcomes in 
11 140 patients with type 2 diabetes mellitus and hypertension (Patel et al., 2007). The 
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primary end point was a composite of major macrovascular and microvascular events. 
After 4.3 years of follow up the active therapy group had a mean reduction in systolic 
blood pressure of 5.6 mm Hg and diastolic blood pressure of 2.2 mm Hg compared to the 
placebo group. The primary endpoint of major macrovascular or microvascular event had 
a relative risk reduction of 9% (HR 0.91, 95% CI 0.83–1.00, p=0.04). Death from 
cardiovascular disease was also reduced by 18% (HR 0.82, 95% CI 0.68–0.98, p=0.03) 
and death from any cause was reduced by 14% (HR 0.86, 95% CI 0.75–0.98, p=0.03). 
The ACCORD trial randomized 4733 people with diabetes to systolic BP targets 
of <120 or <140 mm Hg for a mean follow up of 4.7 years (Cushman et al., 2010).  The 
composite primary outcome of nonfatal MI, nonfatal stroke, or death from cardiovascular 
causes was not significant with an annual rate of 1.87% in the intensive therapy group and 
2.09% in the standard therapy group (HR 0.88; 95% CI 0.73 to 1.06; p=0.20). The annual 
rate of deaths from any cause was also not significant. The annual rate of stroke was 
decreased with intensive therapy (HR 0.59; 95% CI 0.39 to 0.89; p=0.01).  
ACE inhibitors and ARBs have been shown to reduce all-cause mortality, 
cardiovascular events and cardiovascular mortality in patients with diabetes (HOPE 
investigators 2000 and Lindholm et al., 2002). ACE inhibitors and ARBs have also been 
shown to reduce progression of kidney disease in patients with diabetic nephropathy 
(Lewis et al., 1993 and Lewis et al., 2001). For these reasons they are first line therapy 
for hypertension in patients with diabetes (Gilbert et al., 2013).  
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1.9 Achieving metabolic targets 
Despite the evidence and clinical practice guidelines, many patients do not reach 
metabolic targets. In the United Sates, the National Health and Nutrition Examination 
Survey (NHANES) 2009-2010 health survey showed only 55.5% of participants with 
diabetes achieved the target goal of A1C <7.0% and similar rates of compliance were 
seen for blood pressure and lipid recommendations (Wong et al., 2013). The blood 
pressure target <130/80 mm Hg was achieved by 52.8% and LDL cholesterol of <2.6 
mmol/l was achieved by 54.7% of patients with diabetes. The proportion of the NHANES 
2009-2010 population with diabetes who met all three targets was 24.9%. However, there 
is a trend over time from 1999 to 2010 for an improvement in the proportion of the 
NHANES population reaching these targets.   
A similar situation exists in Canada with a large proportion of the population with 
diabetes not meeting targets for glycemic, blood pressure and lipid control. In a chart 
audit of family practices in Ontario the average A1C was 7.9% with 25.7% of patients 
having an A1C at target of <7% and 31.5% had an A1C above 8.4% (Harris et al., 2003). 
In a more recent cross sectional chart audit of 243 primary care physicians in Canada the 
average A1C was 7.3% with 51% of patients achieving a target A1C of <7% (Harris et 
al., 2005). The proportion of patients with optimal control deteriorated over time from 
diagnosis from 69% with an A1C <7% in the first 2 years of diagnosis to 38% at target 
A1C at 15 or more years since diagnosis. In a cross sectional study of primary care 
physicians in 3 Canadian provinces (Nova Scotia, New Brunswick and Prince Edward 
Island) found 54% of patients with diabetes were at target for a blood pressure of <130/80 
(Putnam et al., 2011). A cross sectional study of centers in Canada and Europe found that 
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41.6% of patients with diabetes already on a statin were not at target for LDL (Leiter et 
al., 2011). 
1.10 Medication utilization 
A previous study of the clinical and demographic characteristics of patients 
receiving oral anti hyperglycaemic medications in Ontario residents aged 66 years and 
older on March 31, 2008 identified 387 778 people with diabetes out of  1 752 000 
Ontarians aged 66 years and older (22.1%) (Gomes et al., 2009). The mean duration of 
diabetes was 9.3 years with a standard deviation of 5.1 years. Most individuals (60.1%) 
had at least one prescription for an oral hypoglycaemic agent in the previous year.  
A retrospective cohort study of newly treated elderly hypertensives in Ontario was 
performed using health administrative databases (Friedman et al., 2010). The diabetes 
cohort of 41 236 patients aged 66 years or more in Ontario between 1997 and 2005, 
76.2% were prescribed an ACE inhibitor (n=31 414), 4.9% an ARB (n=2041), 4.7% a 
beta blocker (n=1935), 5.7% a calcium channel blocker (n=2351), and 8.5% a diuretic 
(n=3495).  
A population based study of 105 715 people ≥65 years with newly diagnosed 
diabetes in Ontario between 1994 and 2001 used administrative databases to examine the 
receipt of antihypertensive and lipid-lowering drugs by patients cared for by different 
physician specialties (Shah et al., 2006). The unadjusted lipid lowering prescription rates 
with newly diagnosed diabetes ≥65 years was 23.9% for by those cared for family 
physicians, 28.6% for those cared for by internists and geriatricians and 36.1% by 
endocrinologists. Of the types of lipid lowering medications prescribed, statins accounted 
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for 86.8 to 89.9%. The unadjusted antihypertensive medication prescribing rates were 
66.0% for those cared for by family physicians, 75.1% of those cared for by internists and 
geriatricians and 69.3% of those cared for by endocrinologists. Of these antihypertensive 
medications, 54.2 to 63.1% were ACE inhibitors or ARBs. This study illustrates the low 
rates of the use of vascular protection medications and the differences in prescribing 
among physician specialties.  
The administrative databases of Saskatchewan were used to examine the use of 
anti-platelet agents, statins, and ACE inhibitors by people with type 2 diabetes with and 
without symptomatic atherosclerosis (Brown et al., 2004). The cohort of 12 106 people 
with type 2 diabetes had an average age of 64 years, 55% male, with a mean duration of 
follow up of 5 years. Those patients with type 2 diabetes and coronary artery disease were 
more likely to receive antiplatelet agents at 37% compared to 15% of type 2 diabetes 
patients without coronary artery disease (p <0.001). They were also more likely to receive 
a statin at 29% vs. 15% of patients with type 2 diabetes without coronary artery disease 
(p<0.001) and ACE inhibitors at 60% compared to 43% (p<0.001). Patients with 
cerebrovascular disease and type 2 diabetes were more likely to receive an antiplatelet 
agent at 46% compared to 20% of patients with type 2 diabetes without cerebrovascular 
disease (p<0.001) and ACE inhibitors at 58% compared to 47% (p<0.001) but less likely 
to receive a statin at 16% compared to 20% of those with type 2 diabetes without 
cerebrovascular disease (p=0.001). Patients with peripheral arterial disease and type 2 
diabetes were more likely to receive antiplatelet agents (44%), ACE inhibitors (62%) than 
those without peripheral arterial disease (23%, p<0.001 and 49%, p<0.001 respectively) 
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but not statins (23% vs. 20%, p=0.12). These important cardioprotective medications are 
significantly underused in these populations. 
1.11 Rationale 
DECs are an important part of the diabetes care team (Jones et al., 2013) and will 
continue to be as the burden of diabetes increases in Ontario (Lipscombe et al., 2007). 
DSME is designed to improve patient self-care in many areas including administration of 
medications to manage blood glucose, lipids and blood pressure, SMBG, and monitoring 
for complications (Ismail et al., 2004). There is evidence from RCTs that diabetes 
education improves glycemic control, blood glucose monitoring, blood pressure, weight 
and lipids (Ellis et al., 2004; Norris et al., 2001; Norris et al., 2002; Minet et al., 
2010).   There is little evidence of the effect of diabetes education in a real world setting.  
This study is designed to examine the effect of DEC attendance on prescription 
drug dispensation and retinopathy screening in routine clinical care in Ontario. Patients 
attending DECs learn about diabetes and its complications, and how best to treat it, and 
may become motivated to become advocates for their health.  They may therefore press 
their primary care providers to improve quality of care.  
By using drug prescription data for patients with diabetes it may be possible to 
draw an association between DEC attendance and quality of care.  Large multi-center 
RCTs support the use of statins in most patients over 65 years with diabetes to decrease 
macrovascular risk (Collins et al., 2003; Colhoun et al., 2004). Statins were used as the 
primary outcome as in the over 65 population with diabetes most people would require 
pharmaceutical intervention to reach the target lipid levels making it a good measure of 
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quality of care. People attending DECs would learn about the importance of lipid 
management in preventing diabetes complications and be more likely to accept or seek a 
prescription for a statin from their primary care provider. There is similar strong evidence 
to support the use of glucose lowering medications, antihypertensive medications and 
ACEI/ARBs in this population (UKPDS 33 and 34, Schrier et al., 2002; HOPE 
investigators 2000; Lindholm et al., 2002). DECs also review the importance of these 
interventions and they too can be used as indicators of quality of care and therefore they 
were included as secondary outcomes. As many patients are referred to a DEC to learn 
SMBG so this was also included as a secondary outcome. DEC attendance may serve as a 
reminder for the importance of regular retinopathy screening therefore it was also 
included as a secondary outcome. 
1.11.1 Primary Research Question  
Do diabetic patients aged ≥ 65 years have increased filling of prescriptions for statins 
after attending a DEC in routine clinical care in Ontario? 
1.11.2 Secondary research questions  
Do diabetic patients aged ≥ 65 years have increased filling of prescriptions for glucose 
lowering medications, blood glucose monitoring, ACE inhibitor/ARB, antihypertensive 
medications, and retinopathy screening after attending a DEC in routine clinical care in 
Ontario? 
1.11.3 Hypotheses  
Diabetes education center attendance will be associated with increased use of 
statins in the over 65 population in Ontario. DEC attendance will also be associated with 
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increased the use of glucose lowering medications, antihypertensive medications, ACE 
inhibitor/ARB, SMBG, and retinopathy screening in this population.  
DEC attendance will not be associated with increased use of proton pump inhibitors, 
levothyroxine and otolaryngology care (to test the specificity of the response from DEC 
attendance).
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Chapter 2: Methods 
2.1 Research Design 
This is a population based cohort study of residents of Ontario aged 65 years or 
greater diagnosed with diabetes on or before January 1, 2005. It used health care 
administrative databases of the Ontario Ministry of Health and Long Term Care. These 
databases  include the Ontario drug benefits program database (ODB) which contains the 
prescriptions filled under the provincial formulary for all residents aged ≥65 years; the 
physician service claims database of Ontario Health Insurance Plan (OHIP) which 
includes claims for fee-for-service reimbursement for all physician and optometry 
services provided in Ontario; the hospital discharge abstracts prepared by the Canadian 
Institute for Health Information (CIHI); and a demographic database (Registered Persons 
Database- RPDB) which includes birth and death dates, sex and postal code of home 
residence. Individual patients can be linked between all of these databases and across time 
via their reproducibly encrypted personal health card number.  
DSME in Ontario is delivered mainly through 331 DECs throughout the province 
at academic or community hospitals, community health centers or First Nations 
organizations and is funded in whole or in part by the Ministry of Health and Long Term 
Care. There was no previous administrative database or registry of DEC visits. Therefore, 
a registry of DEC attendance was created by collecting the visit dates and the health card 
numbers of all patients who attended any of the 331 DECs in Ontario in 2006 (Cauch-
Dudek et al., 2013). Data were collected either manually from the DEC charts by trained 
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professional abstractors or directly from electronic registration information. The data 
were linked with the administrative data sources via the patients’ health card number. 
The Ontario Diabetes Database (ODD) was used to identify patients with diabetes. 
The ODD uses an administrative data algorithm to assemble a cohort of all individuals 
with diagnosed non-gestational diabetes in Ontario (Hux et al., 2002). Patients admitted 
to a hospital with a diagnosis of diabetes were identified from the discharge abstracts 
prepared by CIHI. Physician service claims where the diagnosis recorded was diabetes 
were identified from the OHIP records. Patients were identified as having diabetes if they 
had two physician service claims bearing a diagnosis of diabetes within a two year period, 
or one hospitalization with a diagnostic code for diabetes. Once a patient is diagnosed 
with diabetes, they remain in the ODD until death. Physician service and hospitalization 
claims in temporal proximity to records for an obstetrical hospitalization are excluded to 
avoid capturing gestational diabetes in the database. The ODD was validated against two 
independently derived cohorts of individuals with diabetes identified from the ODB 
database and the National Population Health Survey (NPHS) as well as by chart 
abstraction of primary care physician offices and found to have a sensitivity of 86%, 
specificity of 97% and a positive predictive value of 80%. 
2.2 Patient Selection 
The cohort included all residents of Ontario aged 65 years or greater who were 
diagnosed with diabetes on or before January 1, 2005 according to the ODD. The cohort 
was restricted to seniors to ensure that drug dispensation data was complete, as drug 
dispensation information is incomplete for younger patients. The cohort was restricted to 
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those alive until Dec 31, 2007 to insure follow up was complete. Those without a valid 
Ontario postal code were excluded to insure only residents of Ontario were used in the 
analysis. 
2.3 Exposure Variable  
DEC attendance in 2006 by patients in the cohort was determined by linking with 
the DEC database. The index date was assigned as the date of the first DEC visit.  For 
patients who did not attend a DEC, the index date was randomly assigned following the 
same distribution of index dates as seen in attendees.  
2.4 Covariates 
Baseline characteristics were obtained and included:  
1) age at index date 
2) gender  
3) local health integration network (LHIN) of residence at index date (LHINs are 
14 geographic areas created in 2006 which plan, manage and fund health 
services in their region in collaboration with community members and local 
health care providers) 
4) low income flag in ODB (based on eligibility for reduced co-payments in the 
drug benefits programme, requiring documented annual income less than C$16 
018 for individuals or C$24 175 for couples) 
5) duration of diabetes diagnosis at index date, categorized as 1 to <2 years, 2 to 
<5 years, and ≥ 5 years  
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6) comorbidity, assigned as the number of unique Drug Identification Numbers 
(DINs) in the 1 year prior to index date (Schneeweiss et al., 2001) 
7) health care utilization, defined as the number of visits to a primary care 
physician one year prior to index date 
8) diabetes specialist care at least one visit in the year prior to index date 
9) cardiology care at least one visit in the year prior to index date  
10) nephrology care at least one visit in the year prior to index date  
11) hypoglycemia or hyperglycemia hospital admission or emergency department 
visit one year prior to index date 
12) hospital admissions, defined as the number of days in hospital during the one 
year prior to index date 
13) previous coronary or cerebrovascular disease in the 5 years before index date 
2.5 Outcome Variables 
Patients were studied in the 6 month period after their index date for prescriptions 
filled for medications and glucose monitoring supplies from the drug benefits database 
(Figure 2.1). The primary outcome was whether or not a prescription was filled for a 
statin in the 6 months following the index date. 
The secondary outcomes were whether a prescription was filled for blood glucose 
lowering medications, antihypertensive medications in general, ACE inhibitors/ARBs or 
blood glucose monitoring strips. Visits with an optometrist or ophthalmologist for 
retinopathy screening in the 1 year after the index date were determined in both groups 
from the OHIP database.  
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Figure 2.1: Study timeline 
Index date of DEC attendance is set as time 0 with the outcome variables of prescriptions 
filled in the 6 months post index date and healthcare utilization in the 12 months post 
index date. The baseline variables of prescriptions filled in the 6 months prior to index 
date and healthcare utilization in the 12 months prior to index date are also included. 
 
  
-12               - 6                 0         + 6                  + 12 
Prior medication 
dispensation 
Prior healthcare utilization 
Post medication 
dispensation 
Index Date 
Post healthcare utilization 
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To test for the specificity of the response, we selected outcomes where no effect 
from DEC utilization was expected. Therefore, we also examined the filling of 
prescriptions for proton pump inhibitors and levothyroxine in the 6 months after the index 
date and visits with otolaryngologists in the 1 year after the index date. Each outcome 
variable was also examined in the 6 months or 1 year before the index date, to assess 
baseline drug dispensation or physician visits.  
2.6 Analysis  
The baseline characteristics of DEC attendees and non-attendees were compared using p- 
values determined by Student’s t-test for age and Pearson’s Chi Squared test for other 
characteristics, and using standardized difference of the means.  
2.7 Logistic regression 
The primary outcome of prescription filled for statins was compared between 
DEC attendees and non-attendees using logistic regression to adjust for pre-index 
dispensation of statins and all 13 baseline variables. This analysis was repeated for each 
secondary outcome. In each case, the model adjusted for pre-index utilization for that 
category only.  
2.8 Matching using Propensity score  
In observational studies the assignment of patients to the treatment of interest is 
not under the investigators control and there are differences between confounding factors 
between exposure groups (Shah et al., 2005). Multivariate logistic regression is often 
used to control this bias but investigators often construct regression models with few 
covariates as possible to predict outcome.   This makes it more understandable at the 
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expense of the best possible adjustment with interaction and nonlinear terms. Propensity 
scores were proposed by Rosenbaum and Rubin (1983a) as a method to control for 
confounding in observational studies. The propensity score is the conditional probability 
of receiving a treatment given the observed set of potentially confounding variables. It 
can include numerous covariates, interactions and nonlinear terms and can be estimated 
by logistic regression. As the predicted probability of exposure is equal with the same 
propensity score, differences in the exposure allocation can be deemed random. Similar to 
a randomized trial, there is a balance of known confounders between exposure groups 
after adjusting for the propensity score. Like regression modeling it cannot control for 
unknown confounders but the sensitivity of the model to unknown confounders can be 
estimated (Rosenbaum and Rubin, 1983b). 
A propensity score was constructed, with DEC utilization as the dependent 
variable and the 13 baseline socio-demographic and clinical variables and the 9 variables 
for pre-index utilization as the independent variables. The balance of covariates was 
verified between propensity score quintiles; interaction or nonlinear terms were added as 
needed to achieve balance. The DEC attendees and non-attendees were greedy matched 
on the logit of the propensity score, using calipers with a width of 0.6 x the pooled 
standard deviation. This ensures that, on balance, the two groups are balanced on all of 
the known confounders included in the propensity score model. The baseline 
characteristics of the matched cohorts were compared using standardized differences of 
the mean. The standardized difference in the mean is the difference in the means divided 
by the pooled estimate of the standard deviation of the variable (Austin, 2008). Unlike 
significance testing, it is not affected by sample size and is therefore more useful to 
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compare groups when using large datasets. Values of 0.1 or greater suggest a potentially 
meaningful imbalance in a particular covariate between groups. The risk difference 
between those attending a DEC and those not attending a DEC for the frequency of filling 
prescriptions for statins was calculated from contingency tables.  The statistical 
significance of this difference was ascertained using McNemar’s test. The analysis was 
repeated for all secondary outcomes.  
2.9 Ethics approval 
 Ethics approval was obtained from the Sunnybrook Health Sciences Centre 
Research Ethics Board. 
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Chapter 3: Results 
3.1 Logistic Regression 
3.1.1 Baseline characteristics 
There were 350 734 people with diabetes ≥65 as of January 1, 2005. Of them, 54 
575 (15.6%) were excluded because they died prior to December 31, 2007, leaving 
296,159 in the cohort. Of them, 22,606 (7.6%) attended a DEC in 2006. The baseline 
characteristics of this population are outlined in Table 3.1. The groups differed on all 
variables examined. The DEC attendees were slightly younger, were more likely to be 
male, and were less likely to have low income. LHIN of residence was variable between 
non-attendees and DEC attendees. Patients who attended a DEC were more likely to have 
a duration of diabetes from 1-2 years or greater than 5 years.  The comorbidity index 
expressed as the number of distinct DINs for each individual and the rate of known 
coronary and cerebrovascular disease was higher in DEC attendees. Patients who attended 
a DEC in 2006 were more likely to have a greater number of primary care visits, and 
received diabetes specialist care, nephrology care and cardiology care in the year prior to 
the index date. DEC attendees also had a higher number of hospital inpatient days and 
were more likely to have hospital admissions and emergency room visits for 
hypoglycaemia and hyperglycaemia in the year prior to the index date. The rates of 
prescriptions filled for medications in the 6 months prior to the index date were higher for 
those who attended a DEC in 2006 for statins, glucose lowering medications, 
antihypertensive medications in general, ACE inhibitors and ARBs and glucose 
monitoring strips than for those who did not attend a DEC.  Proton pump inhibitor and 
levothyroxine prescription rates were also higher in the DEC attendee group.  DEC  
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Table 3.1: Baseline characteristics at index date 
 
Variable  Value  Non-attendees DEC Attendees  P-
value  
   n (%) 273,553 (92.4%)  22,606 (7.6%)    
Age  Mean ± SD 75.7± 6.7 73.8 ± 5.5 <0.001 
Gender 
  
Female n (%) 140,747 (51.5%)  11,383 (50.4%)  0.002 
  Male n (%) 132,806 (48.5%)  11,223 (49.6%)  
LHIN 1. Erie St. Clair n (%) 15,578 (5.7%) 1,481 (6.6%) <0.001 
2. South West n (%) 19,870 (7.3%)  1,845 (8.2%) 
3. Waterloo Wellington  
n (%) 
11,576 (4.2%)  818 (3.6%) 
4. Hamilton Niagara 
Haldimand Brant n (%) 
30,297 (11.1%) 3,272 (14.5%) 
5. Central West n (%) 14,502 (5.3%) 832 (3.7%) 
6. Mississauga Halton  
n (%) 
19,730 (7.2%) 1,466 (6.5%) 
7. Toronto Central n (%) 26,427 (9.7%) 1,035 (4.6%) 
8. Central  n (%) 37,137 (13.6%)  2,115 (9.4%) 
9. Central East n (%) 35,973 (13.2%) 2,689 (11.9%) 
10. South East n (%) 11,567 (4.2%) 961 (4.3%) 
11. Champlain n (%) 23,160 (8.5%) 2,246 (9.9%) 
12. North Simcoe Muskoka  
n (%) 
8,361 (3.1%) 1,320 (5.8%) 
13. North East n (%) 14,006 (5.1%) 1,723 (7.6%) 
14. North West n (%) 4,952 (1.8%) 795 (3.5%) 
 Missing LHIN n (%) 417 (0.2%) 8 (0.0%) 
Low income   n (%) 77,425 (28.3%)  5,355 (23.7%)  <0.001  
Duration of diabetes  
  
A. 1-2 y n (%) 13,620 (5.0%)  1,290 (5.7%)  <0.001 
B. 2-5 y n (%) 58,379 (21.3%)  4,055 (17.9%)  
C. >5 y n (%) 201,554 (73.7%)  17,261 (76.4%)  
Comorbidity (#DINs)  Mean ± SD 10.8 ± 7.0 13.4 ± 6.7 <0.001 
Primary Care visits Mean ± SD 8.3 ± 8.5 8.5 ± 6.1 <0.001 
Diabetes specialist  n (%) 42,302 (15.5%) 8,473 (37.5%) <0.001 
Nephrology  n (%) 11,609 (4.2%) 1,820 (8.1%) <0.001  
Cardiology  n (%) 41,276 (15.1%) 5,044 (22.3%) <0.001  
Hospital admission/ 
ER visit for 
hypo/hyperglycemia  
n (%) 2,285 (0.8%) 560 (2.5%) <0.001  
Hospital Inpatient 
Days  
Mean ± SD 1.7 ± 8.4 2.2 ± 7.6 <0.001 
Coronary/ 
cerebrovascular 
disease   
n (%) 27,390 (10.0%) 3,013 (13.3%) <0.001 
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Variable  Value  Non-attendees DEC Attendees  P-value  
Statins  n (%) 145,875 (53.3%)  15,405 (68.1%)  <0.001  
Glucose lowering medications n (%) 158,567 (58.0%)  18,595 (82.3%)  <0.001  
Antihypertensive medications  n (%) 212,112 (77.5%)  20,173 (89.2%)  <0.001  
ACE inhibitors/ARBs n (%) 174,710 (63.9%)  17,704 (78.3%)  <0.001  
Glucose monitoring strips  n (%) 116,017 (42.4%)  17,115 (75.7%)  <0.001  
Ophthalmology/ optometry  n (%) 164,512 (60.1%)  17,442 (77.2%)  <0.001  
Proton pump inhibitors n (%) 55,751 (20.4%)  5,790 (25.6%)  <0.001  
Levothyroxine  n (%) 37,281 (13.6%)  3,655 (16.2%)  <0.001  
Otolaryngology n (%) 16,550 (6.1%)  1,849 (8.2%)  <0.001  
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attendees were more likely to have ophthalmology/optometry and otolaryngology visits 
than non-attendees in the year prior to the index date.  
3.1.2 Medication and physician visits after index date by logistic regression 
As all variables differed at baseline between DEC attendees and non-attendees the 
model was adjusted for all of these variables in the logistic regression. The results of the 
logistic regression are outlined in Table 3.2. The primary outcome of statin use in the 6 
months following the index date was associated with DEC attendance with an OR of 1.45 
(95% CI 1.37, 1.53, p<0.001). The secondary outcomes were also associated with DEC 
attendance. The use of glucose lowering medications in the 6 months following index 
date was associated with DEC attendance with an OR of 2.20 (95% CI 2.04, 2.37, 
p<0.001). Antihypertensive medication use is associated with DEC attendance with an 
OR of 1.49 (95% CI 1.38, 1.62, p<0.001) as were ACE inhibitors and ARBs with an OR 
of 1.47 (95% CI 1.38, 1.57, p<0.001). The use of glucose monitoring strips in the 6 
months following the index date was associated with DEC attendance with an OR of 3.82 
(95% CI 3.67, 3.98, p<0.001). Ophthalmology and optometry care in the 1 year after the 
index date was associated with DEC attendance with an OR of 1.56 (95% CI 1.50, 1.62, 
p<0.001). As expected, DEC attendance did not have an impact on proton pump inhibitor 
use in the 6 months after the index date (OR 1.01, 95% CI 0.96, 1.07, p=0.6) or 
otolaryngology visits in the 1 year after index date (OR 1.05 95% CI 0.99, 1.11, p=0.09) 
as these were used to test the specificity of the response. However, levothyroxine use was 
slightly associated with DEC attendance with an OR of 1.17 (95% CI 1.01, 1.36, p=0.04) 
in the 6 months after the index date. 
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Table 3.2: Association of medication dispensation and physician visits with DEC 
attendance by logistic regression 
 
Medication   Odds Ratio  95% CI  P-value 
Statins  1.45  1.37, 1.53  <0.001  
Glucose lowering medications  2.20  2.04, 2.37  <0.001  
Antihypertensive medications 1.49  1.38, 1.62  <0.001  
ACE inhibitors/ARBs  1.47  1.38, 1.57  <0.001  
Glucose monitoring strips  3.82  3.67, 3.98  <0.001  
Ophthalmology/ optometry  1.56  1.50, 1.62  <0.001  
Proton pump inhibitors 1.01  0.96, 1.07  0.6  
Levothyroxine  1.17  1.01, 1.36  0.04  
Otolaryngology  1.05  0.99, 1.11  0.09  
 
  
  
49 
 
3.2 Matching using Propensity Score 
3.2.1 Baseline Characteristics 
 Using the propensity score to obtain a matched cohort of non-attendees to the 22 
606 DEC attendees, a sample size of 45 212 was obtained with 22 606 in each group 
(Table 3.3). They were well matched for all baseline characteristics as demonstrated by 
the standardized difference of all variables being close to 0.  The average age of the 
cohort was 73.8 years with an equal proportion of male and females. A similar proportion 
of DEC attendees and non-attendees were from each LHIN. 23.6% of the population had 
a low income tag in ODB. Both groups had a similar number of members with the same 
duration of diabetes and comorbidity score. Both groups had similar numbers of primary 
care visits and likelihood of receiving specialist care. A similar number of patients in each 
group filled prescriptions for statins, glucose lowering medications, antihypertensive 
medications, ACE inhibitors and ARBs, glucose monitoring strips, proton pump 
inhibitors and levothyroxine. 
3.2.2 Medication dispensation and physician visits after index date in the 
propensity score matched cohort 
 The absolute rates of medication dispensation in the 6 months after index date and 
of physician visits in the 1 year after index date for DEC attendees and non-attendees in 
the cohort matched by propensity score are shown in Table 3.4. The proportion of DEC 
attendees who filled a prescription for a statin in the 6 months after the index date was 
70.6% compared to 69.4% of non-attendees (p=0.003) with risk difference of 1.2%.  
Prescriptions for glucose lowering medications were filled by 83.7% of DEC attendees in 
the 6 months after index date compared to 82.0% of non-attendees (p <0.0001) with a risk  
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Table 3.3: Baseline characteristics of cohort post propensity score match 
Variable  Value  
 
 
Non-attendees DEC 
Attendees  
Standardized 
difference of 
the mean 
    N=22,606 N=22,606  
Age  Mean ± SD 73.8 ± 5.6 73.8 ± 5.5 0.01 
Gender 
  
Female n (%) 11,316 (50.1%) 11,383 (50.4%) 0.01 
Male n (%) 11,290 (49.9%) 11,223 (49.6%) 
LHIN 1. Erie St. Clair n (%) 1,518 (6.7%) 1,481 (6.6%) 0.03 
2. South West n (%) 1,890 (8.4%) 1,845 (8.2%) 
3. Waterloo Wellington  
n (%) 
831 (3.7%) 818 (3.6%) 
4. Hamilton Niagara 
Haldimand Brant n (%) 
3,187 (14.1%) 3,272 (14.5%) 
5. Central West n (%) 851 (3.8%) 832 (3.7%) 
6. Mississauga Halton  
n (%) 
1,453 (6.4%) 1,466 (6.5%) 
7. Toronto Central n (%) 1,023 (4.5%) 1,035 (4.6%) 
8. Central n (%) 2,148 (9.5%) 2,115 (9.4%) 
9. Central East n (%) 2,702 (12.0%) 2,689 (11.9%) 
10. South East n (%) 1,031 (4.6%) 961 (4.3%) 
11. Champlain n (%) 2,162 (9.6%) 2,246 (9.9%) 
12. North Simcoe 
Muskoka n (%) 
1,285 (5.7%) 1,320 (5.8%) 
13. North East n (%) 1,732 (7.7%) 1,723 (7.6%) 
14. North West n (%) 789 (3.5%) 795 (3.5%) 
Missing LHIN n (%) <=5 (0.0%) 8 (0.0%) 
Low income   n (%) 5,315 (23.5%) 5,355 (23.7%)  0 
Duration of diabetes  
  
A. 1-2 y n (%) 1,286 (5.7%)  1,290 (5.7%) 0.01 
 B. 2-5 y n (%) 4,131 (18.3%) 4,055 (17.9%) 
C. >5 y n (%) 17,189 (76.0%) 17,261 (76.4%) 
Comorbidity 
(#DINs)  
Mean ± SD 13.3 ± 6.8 13.4 ± 6.7 0.01 
Primary Care visits Mean ± SD 8.8 ± 7.0 8.5 ± 6.1 0.04 
Number of primary 
care visits 
0 visits n (%) 532 (2.4%) 685 (3.0%)  0.05 
1-2 visits n (%) 1,584 (7.0%) 1,591 (7.0%)  
3-6 visits n (%) 7,544 (33.4%) 7,422 (32.8%)  
7-12 visits n (%) 8,698 (38.5%) 8,477 (37.5%)  
≥13 visits n (%) 4,248 (18.8%) 4,431 (19.6%)  
Diabetes specialist  n (%) 8,267 (36.6%) 8,473 (37.5%) 0.02 
Nephrology  n (%) 1,780 (7.9%) 1,820 (8.1%) 0.01 
Cardiology  n (%) 4,985 (22.1%) 5,044 (22.3%) 0.01 
Hospital admission/ 
ER visit for hypo/ 
hyperglycemia  
n (%) 540 (2.4%) 560 (2.5%) 0.01 
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Variable  Value  
 
 
Non-attendees DEC 
Attendees  
Standardized 
difference of 
the mean 
Hospital Inpatient 
Days  
Mean ± SD 2.5 ± 9.5 2.2 ± 7.6 0.04 
Coronary/ 
cerebrovascular 
disease  
n (%) 2,967 (13.1%) 3,013 (13.3%) 0.01 
Statins  n (%)  15,561 (68.8%) 15,405 (68.1%) 0.01 
Glucose lowering 
medications  
n (%) 18,689 (82.7%) 18,595 (82.3%) 0.01 
Antihypertensive 
medications  
n (%) 20,325 (89.9%) 20,173 (89.2%) 0.02 
ACE 
inhibitors/ARBs  
n (%) 17,838 (78.9%) 17,704 (78.3%) 0.01 
Glucose monitoring 
strips  
n (%) 17,135 (75.8%) 17,115 (75.7%) 0 
Ophthalmology/ 
optometry  
n (%) 17,527 (77.5%) 17,442 (77.2%) 0.01 
Proton pump 
inhibitors 
n (%) 5,805 (25.7%) 5,790 (25.6%) 0 
Levothyroxine  n (%) 3,584 (15.9%) 3,655 (16.2%) 0.01 
Otolaryngology n (%) 1,797 (7.9%) 1,849 (8.2%) 0.01 
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Table 3.4: Absolute rates of medication and healthcare utilization in the propensity 
score matched cohort after the index date 
 
Medication Non-attendees  
n (%) 
DEC attendees  
n (%) 
Risk 
Difference 
P-value 
Statins 15687 (69.4%) 15965 (70.6%) 1.2% 0.003 
Glucose lowering 
medications 
18534 (82.0%) 18931 (83.7%) 1.8% <0.0001 
Antihypertensive 
medications 
20286 (89.7%) 20397 (90.2%) 0.5% 0.07 
ACE inhibitors/ARBs  17830 (78.9%) 18036 (79.8%) 0.9% 0.01 
Glucose monitoring strips  14835 (65.6%) 18588 (82.2%) 16.6% <0.0001 
Ophthalmology/optometry 16437 (72.7%) 17797 (78.7%) 6.0% <0.0001 
Proton pump inhibitors 6055 (26.8%) 6119 (27.1%) 0.3% 0.5 
Levothyroxine  3642 (16.1%) 3747 (16.6%) 0.5% 0.2 
Otolaryngology 1682 (7.4%) 1763 (7.8%) 0.4% 0.2 
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difference of 1.8%. There was no difference in rates of antihypertensive use in the 6 
months after index date between DEC attendees and non-attendees (90.2% vs. 89.7%, 
p=0.07). However, the rate of prescriptions filled for ACE inhibitors and ARBs was 
79.8% in DEC attendees compared to 78.9% in non-attendees in the 6 months after index 
date (p=0.01) with a risk difference of 0.9%. Glucose monitoring strips were obtained by 
82.2% of DEC attendees compared to 65.6% of non-attendees after the index date 
(p<0.001) with a risk difference of 16.6%. Visits to ophthalmology/optometry were 
higher in DEC attendees at 78.7% compared to 72.7% in non-attendees in the year 
following the index date (p<0.0001) with a risk difference of 6.0%. As expected, DEC 
attendance did not have an impact on prescriptions filled for proton pump inhibitors 
(27.1% vs. 26.8%, p=0.5) and levothyroxine (16.6% vs. 16.1%, p=0.2) in the 6 months 
following the index date or visits to otolaryngology in the 1 year following the index date 
(7.8% vs. 7.4%, p=0.2) as these were used to test the specificity of the response.
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Chapter 4: Discussion 
4.1  Characteristics of people with Diabetes over age 65 in 2006 attending DEC 
vs. not attending a DEC in Ontario in the cohort 
This study included all of those diagnosed with Diabetes in Ontario and aged 65 
years and older on January 1, 2005. Only a small portion of these people attended a DEC 
in 2006. This is a snapshot of a one-year time frame so it does not capture people who 
had attended a DEC in previous years. Inevitably, many patients who are referred to 
DSME ultimately do not attend. The attendance rate was lower than seen in other studies 
(Coonrod et al., 1994; Shah et al., 2009; Ruppert et al., 2010). This study measured DEC 
attendance in a 1 year period in a population based cohort. Other studies measured 
diabetes education since diagnosis. They are surveys with voluntary participation and 
diabetes education is self-reported.  In a survey of people with diabetes mainly distributed 
through pharmacies in Ontario 30% of people reported having attended a DEC in the year 
prior (Shah et al., 2009). A nationwide survey in the United States found that 35.1% of 
people with diabetes had attended diabetes education since diagnosis (Coonrod et al., 
1994). In a study from rural Pennsylvania 65% of people with reported they had never 
received DSME and 76% of those had never received a referral to DSME (Ruppert et al., 
2010). 83% of those referred to DSME attended.    
The population attending the DECs in Ontario were slightly younger, more likely 
to be male and less likely to be of low income status than those who did not attend a DEC 
in 2006. These characteristics are similar to those seen in other studies. A nationwide 
survey in the United States showed that diabetes education attendance was associated 
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with younger age, African-American ethnicity, and higher education (Coonrod et al., 
1994). Age greater than 70 years was associated with lower participation in an American 
study of diabetes education in people over 60 (Glasgow et al., 1991). Female sex and 
larger BMI predicted DEC attendance in a study in a Philadelphia academic family 
practice (Graziani et al., 1999). Those who attended a DEC in Ontario in the 6 months 
after diagnosis were less likely to be of low income status, less likely to be a recent 
immigrant, and more likely to be of rural residence than those who did not attend (Cauch-
Dudek et al., 2013).  
DEC attendees were more likely to have a shorter duration of diabetes than non-
attendees, which is not surprising as newly diagnosed are in need of DSME. Despite this, 
only 20.6% of all adults with newly diagnosed diabetes attended a DEC within 6 months 
of diagnosis in Ontario in 2006 (Cauch-Dudek et al., 2013). In a survey of people with 
diabetes mainly distributed through pharmacies in Ontario DEC attendance was also 
associated with shorter duration of diabetes (Shah et al., 2009). Those with a long 
duration of diabetes (>5 years) were also more likely to attend a DEC as these patients 
may need an update in their education or have comorbidities that have triggered referral. 
This is evident as the comorbidity score (defined as the number of distinct DINs in 1 
year) was higher in those who attended the DEC in 2006 than those who did not.  A 
nationwide survey in the United States showed that diabetes education attendance was 
associated with insulin use and more diabetes complications (Coonrod et al., 1994). In a 
study from rural Pennsylvania, those individuals with more risk factors and comorbidities 
were more likely to be referred to diabetes education (Ruppert et al., 2010).   
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The number of primary care visits in the year prior to the index date was slightly 
higher in those who attended a DEC, suggesting that DECs are not replacing normal 
primary care but are used as an adjunct to it. The same result was seen in the cohort study 
of all newly diagnosed adults with diabetes in Ontario that used the same DEC registry 
(Cauch-Dudek et al., 2013). In a survey of people with diabetes mainly distributed 
through pharmacies in Ontario DEC attendance was associated with regular primary care 
visits and regular diabetes specialist care (Shah et al.,2009).  
DEC attendees were more likely to have had a hospital admission and emergency 
room visits for hypoglycemia or hyperglycemia and more hospital inpatient days for all 
causes than non-attendees in the year prior to the index date. Overall, DEC attendees are a 
much sicker population than non-attendees as evidenced by their comorbidity score, rates 
of coronary and cerebrovascular disease, and used greater health care resources including 
specialist and primary care than non-attendees in the year prior to the index date. These 
physician and hospital visits provided more contact time with this group and provided an 
opportunity for referral to a DEC. The presentation with complications of diabetes 
demonstrated a need for diabetes education that may have prompted the visit to a DEC.  
Those elderly who attended a DEC in 2006 had a higher rate of prescriptions filled 
in the 6 months prior to the index date than those who did not attend a DEC. This was 
true of all medications studied related to the management of diabetes and its 
complications (statins, glucose lowering medications, antihypertensive medications, ACE 
inhibitors and ARBs, and glucose monitoring strips) as well as proton pump inhibitors 
and levothyroxine which were used to test the specificity of the response. As the rates of 
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prescriptions filled is increased for all medications examined in the DEC attendee group, 
this may suggest that the DEC attendee group is a sicker group. This is also supported by 
their comorbidity score and rate of hospitalization. It might also suggest that this group 
was already more compliant with medications as prescribed and with health care follow 
up. Two American studies found insulin use to be associated with DEC attendance 
(Coonrod et al., 1994; Graziani et al., 1999). 
Many studies were RCTs with groups matched for baseline characteristics in 
which the control group also received some form of diabetes education. Consequently it is 
difficult to compare those trials to this cohort population for the demographic 
characteristics, health care utilization, and medication dispensation at baseline. The 
studies using surveys of people with diabetes do not report medication use. Hence, this 
cohort study provides a real world picture of individuals with diabetes attending DEC 
compared to those who do not. 
4.2 Logistic Regression results 
The primary outcome of prescriptions filled for statins in the 6 months after the 
index date was higher in the DEC attendees, suggesting DEC attendance is associated 
with the increased use of statins. DECs teach about the cardiovascular complications of 
diabetes and self-management behaviors to reduce these risks, such as taking statins and 
antihypertensive medications. This knowledge may increase attendees’ likelihood to fill 
and take the prescription for a statin and to ask their care provider about statin therapy if 
they have not already been prescribed a statin.  
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The results from routine clinical care mirror those previously reported in 
randomized trials of diabetes education interventions. Lipid lowering medication use in 
the intervention arm of DESMOND was higher than the control population but not 
statistically significant using NHS data (Gillett et al., 2010). The lipid values were not 
different between the groups (Davies et al., 2008).  A RCT of group diabetes education 
compared to usual care showed lipid active medication increased over the study period in 
both groups without significant differences in lipid profiles other than an increase in HDL 
in group care (Trento et al., 2002). 
However, the finding of increased lipid lowering medication utilization following 
DSME has not been universal. Many prior studies of diabetes education showed no 
difference in lipid lowering medication use between groups. Most were RCTs that 
compared a new structured diabetes education program to standard care that also included 
diabetes education. The primary outcome of many of these studies is reduction in A1C 
with statin use or lipid levels as a secondary outcome.  There was no difference in statin 
use in patients with diabetes participating in Disease Management Programs in Germany 
compared to those who did not participate (Berthold et al., 2011). Despite this, there was 
an improvement in LDL cholesterol.  A meta–analysis of studies of nurse led DSME 
showed small changes on lipid levels (Tshiananga et al., 2012). There was an increase in 
HDL of 0.009 mmol/L (p=0.018), a decrease in total cholesterol of -0.032 mmol/L 
(p=0.010), a decrease in LDL of -0.010 mmol/L (p=0.016), and a decrease in triglycerides 
of -0.237 mmol/L which was non-significant. Although the studies included in this meta-
analysis did not include information on statin use, it is possible DSME had an effect given 
the change in lipid levels.  
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The secondary outcomes were also found to have an increase associated with DEC 
attendance. The prescriptions filled for glucose lowering medications in the 6 months 
after the index date was higher in the DEC attendees suggesting DEC attendance is 
associated with the increased use glucose lowering medications. This follows as many 
patients are referred to DECs for education when starting on a new diabetes therapy such 
as learning insulin administration and adjustment.  
The use of glucose lowering medications has also found to be associated with 
DSME in previous studies. For example, self-reported use of glucose lowering 
medication was higher in the intervention group of diabetes education compared to the 
control group in a study of a DSME program in Malaysia (Tan et al., 2011). This was 
correlated to the decrease in A1C in the intervention group (r=-0.27, p=0.001).  
However, the effect of DSME on glucose lowering medications was variable in 
other studies with the increased use being attributed to greater medication compliance in 
some studies and the decrease use being attributed to better lifestyle choices in other 
studies. A RCT of group diabetes education compared to usual care showed a reduction in 
the doses of hypoglycemic agents over 4 years in the intervention group compared to an 
increase in dose in the control group (Trento et al., 2002). The A1C remained constant in 
the intervention group but increased significantly in the control group. A similar result 
was seen in the Cochrane review of group DSME, where the participants required fewer 
diabetes medications compared to controls in the 5 included studies (OR 11.8, 95% CI 
5.2-26.9; p<0.00001, I
2
=0) (Deakin et al., 2005). Even with fewer medications used there 
was a reduction in A1C which was maintained at follow up suggesting the use of fewer 
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diabetes medications may be related to greater diabetes knowledge and self-care 
behaviors that prevented further increases in medications.   
In other studies there was no difference seen in the use of glucose lowering 
medications between groups and no statistically significant reduction in A1C seen 
between groups. In DESMOND, the use of glitazones and sulphonylureas were not 
different and there was a non-significant trend toward an increased use of metformin in 
the DESMOND group (Gillett et al., 2010). The reduction in A1C was greater in the 
intervention group compared to the control group of DESMOND, −1.49% (95% CI 
−1.69% to −1.29%) compared with −1.21% (95% CI −1.40% to −1.02%), but after 
adjustment for baseline characteristics and cluster effect the difference was not 
statistically significant (Davies et al., 2008). A RCT of DSME aimed at changing the self-
care behaviours of SMBG, healthy eating and smoking cessation to usual care showed 
that both groups changed the dose or frequency of oral agent therapy during the study 
with no difference between groups (Jones et al., 2003). Both groups also increased the 
frequency of insulin injection during the study. There was no reduction in A1C between 
groups unless the subgroup of those who reached the active or maintenance phase of the 
behavior change was examined. 
The prescriptions filled for antihypertensive medications in the 6 months after the 
index date was increased in DEC attendees. Prescriptions filled for ACE inhibitors and 
ARBs was also increased in the 6 months after the index date in DEC attendees. DECs 
teach about the cardiovascular and renal complications of diabetes and self-management 
behaviors to reduce these risks that include blood pressure control and the use of ACE 
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inhibitors and ARBs. This knowledge may increase attendees’ likelihood to fill and take 
the prescription for antihypertensive medications.  A decline in persistence of 
antihypertensive therapy is seen after initiation in newly treated elderly hypertensive 
individuals in Ontario with the diabetic cohort having a therapy persistence of 74.2% over 
1 year and 67.3% over 2 years (Friedman et al., 2010). Therefore, any intervention which 
improves compliance and persistence is beneficial. 
Other studies have shown an increase in antihypertensive medication use in both 
groups.  A RCT of group diabetes education compared to usual care which included 
individual diabetes education, showed antihypertensive medication use increased over the 
study period in both groups with a decrease in diastolic blood pressure in both groups 
(Trento et al., 2002). The increase in antihypertensive use and decrease in blood pressure 
may be related to the effect of diabetes education in both groups.  
Many of the studies of diabetes education do not measure the use of 
antihypertensive medications but instead look at blood pressure. DESMOND showed no 
difference in blood pressure between groups at the end of the study period (Davies et al., 
2008). A meta–analysis of studies of nurse-led DSME showed the effect on blood 
pressure was non-significant compared to the control group with a net decrease in 
diastolic blood pressure of −2.291 mmHg (p=0.064) and in systolic blood pressure of 
−1.847 mmHg (p=0.361) (Tshiananga et al., 2012). These studies did not examine 
antihypertensive use by participants but it is possible that DSME increased their use given 
the trend down in blood pressure.  
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Prescriptions filled for glucose monitoring strips was increased in the 6 months 
after the index date in DEC attendees. When attending a DEC, patients are instructed to 
monitor their blood glucose to aid in the optimization of their treatment and often asked 
to bring a blood glucose log to follow up visits at the DEC or with their health care 
provider. Therefore it makes sense that DEC attendance would be strongly associated 
with the use of glucose monitoring strips in the next 6 months.  
Similar increases in SMBG were seen in RCTs of diabetes education regardless of 
effect on A1C. SMBG increased in the intervention group at 2.88/week (95% CI 2.53-
3.23) compared to the control group at 0.62/week (95% CI 0.35-0.89, p<0.001) during the 
study period of a DSME program in Malaysia (Tan et al., 2011). The increase in SMBG 
in the intervention group was correlated with the decrease in A1C (r = -0.28, p=0.001). A 
RCT of DSME aimed at changing the self-care behaviours of SMBG, significantly 
increase testing frequency from 1.4 to 1.6 tests per day as measured by downloaded meter 
memory compared to a slight decrease in the control group (p=0.002) (Jones et al., 2003). 
The reduction in A1C was not significant between groups in the intention treat analysis 
but was for the subgroup of those who reached or maintained action of self-glucose 
monitoring over the course of the trial with an A1C of 7.78% compared to 8.30% in those 
who stayed in the pre-action phase (p< 0.003). The reduction in A1C was seen regardless 
of using oral agents or insulin. 
The odds of receiving care by ophthalmology or optometry in the 1 year after the 
index date was higher for DEC attendees.  The development of diabetic retinopathy, and 
the importance of screening for it with appropriate eye examinations, is reviewed at DECs 
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so it follows that DEC attendance would be associated with an increase in care by 
ophthalmology or optometry as the DEC visit may serve as a reminder to the patient to 
see their eye doctor.  
A similar association with diabetes education and eye care was seen in other 
studies. In a survey of people with diabetes mainly distributed through pharmacies in 
Ontario DEC attendance was associated with retinal screening in the following 2 years 
(Shah et al., 2009). In a RCT of nurse case manager led DSME the rate of 
ophthalmological examination was 68% compared to 26% in the control group (Gabbay 
et al., 2006). 
Proton pump inhibitors, levothyroxine and otolaryngology visits were used to 
demonstrate the specificity of the response to DEC attendance of the diabetes related 
outcomes. As expected, the prescriptions filled for proton pump inhibitors in the 6 months 
after the index date in DEC attendees and non-attendees, was not different. Receiving 
care by otolaryngology in the 1 year after the index date was not different between 
groups. Both these outcomes are not related to diabetes and its management therefore it 
was expected that no association would be seen with DEC attendance. However, 
prescriptions filled for levothyroxine in the 6 months after the index date was slightly 
higher in the DEC attendees than non-attendees. This was not expected to be different 
between groups as it is unrelated to the management of diabetes and its complications. 
However, as many patients with diabetes are managed by diabetes specialists who are 
endocrinologists or internists, they may be more likely to have been screened for 
hypothyroidism, and treated when diagnosed. The DEC attendees were more likely to see 
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these physicians than non-attendees and therefore be more likely to have their 
hypothyroidism diagnosed and treated. They may be a more health-aware population so 
more laboratory tests are performed as they see physicians more often and may be more 
likely to be compliant with treatments that are prescribed. Although care by a diabetes 
specialist and number of primary care visits in the year prior to the index date were 
adjusted for, they were not adjusted for in 6 months after index date which is when this 
difference was seen. The small increased increase in levothyroxine prescriptions also may 
suggest it is a sicker population overall so more attention is paid to all metabolic 
parameters. For these reasons levothyroxine may not have been a good choice as to test 
the specificity of the response to DEC attendance as it is confounded in diabetes patients. 
4.3 Propensity Match results 
The use of propensity scores lead to extremely well matched cohorts. For the 
primary outcome with propensity score matching, the rate of prescriptions filled for 
statins by DEC attendees was greater than in non-attendees in the 6 months after the 
index date.  While there is a statistically significant association of statin use with DEC 
attendance, the effect is not large in the matched population.  It is noted that in the 6 
months prior to the index date 68.1% of DEC attendees and 68.8% of non-attendees filled 
a prescription for a statin so the dispensation of statins in this cohort was already fairly 
high in both groups leaving little room an effect of DEC attendance yet the small 
difference was statistically significant. 
This study examined outcomes in patients in routine clinical care. The results are 
similar to what has been seen in RCTs of DSME. There was a trend toward increased use 
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of lipid lowering medication use in the intervention arm of DESMOND compared to the 
control population but this was not statistically significant (Gillett et al., 2010). The lipid 
values were also not different between the groups (Davies et al., 2008). An increase in 
lipid-active medication was seen over the study period in both groups in a RCT of group 
diabetes education compared to usual care without significant differences in lipid profiles 
(Trento et al., 2002).   
Many RCTs of diabetes education showed no significant difference in lipid 
lowering medication use between groups with little or no effect on lipid levels. These 
RCTs had much smaller sample sizes than our population based cohort study so while 
there was often a trend toward an increase in lipid lowering medication use, it was not 
statistically significant. Despite an improvement in LDL cholesterol, there was no 
difference in statin use in patients with diabetes participating in Disease Management 
Programs in Germany compared to those who did not participate (Berthold et al., 2011).  
For most of the secondary outcomes, an association with DEC attendance was 
seen. In most cases the effect was small using the propensity score match. The rate of 
prescriptions filled for glucose lowering medications in the 6 months after the index date 
in DEC attendees was slightly higher than in non-attendees. Many patients are referred to 
DECs at the time of initiation of new glucose lowering therapy so it is expected the 
prescriptions filled for glucose lowering medications would be higher in DEC attendees 
than non-attendees.  
An increase in glucose lowering medications was seen in other studies of diabetes 
education. A study of a DSME program which showed an increase in self-reported use of 
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glucose lowering medication in the intervention group of diabetes education (91.42%, 
95% CI 89.12–93.72) compared to the control group (84.4%, 95% CI 81.76–87.20, 
p=0.008) (Tan et al.,2011). This was correlated to the decrease in A1C in the intervention 
group (r= - 0.27, p=0.001). There was also an increase in oral diabetic agent and insulin 
prescriptions in patients with diabetes enrolled in Disease Management Programs in 
Germany compared to those who were not (Berthold et al., 2011). 
Other studies showed no significant difference seen in the use of glucose lowering 
medications between groups and no reduction in A1C seen between groups. In 
DESMOND there was no difference in the use of glitazones and sulphonylureas between 
groups with a non-significant trend toward an increased use of metformin in the 
DESMOND group (Gillett et al., 2010). Both groups changed the dose or frequency of 
oral agent therapy and increased the frequency of insulin injection during the study with 
no difference between groups during a RCT of DSME aimed at changing the self-care 
behaviours (Jones et al., 2003).  
However, other studies showed a reduction in the dose of glucose lowering 
medications with diabetes education which was attributed to better adherence to improved 
lifestyle choices related to greater diabetes knowledge and self-care behaviors in the 
intervention groups as A1C improved or remained constant compared to an increase in 
the control group.  This was seen in a RCT of group diabetes education with a reduction 
in the doses of hypoglycemic agents over 4 years in the intervention group compared to 
an increase in the control group while the A1C remained constant in the intervention 
group but increased in the control group  (Trento et al., 2002). A similar result was seen 
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in the Cochrane review of group DSME where participants required fewer diabetes 
medications compared to controls in the 5 included studies (OR 11.8, 95% CI 5.2-26.9; 
p<0.00001, I
2
=0) (Deakin et al., 2005). There was a reduction in A1C that was 
maintained at follow up.  
The rate of prescriptions filled for antihypertensive medications was not different 
between DEC attendees and non-attendees. The use of hypertensive medications in this 
cohort was already high at baseline in both groups.  However, the rate of prescriptions 
filled for ACE inhibitors and ARBs was slightly higher in DEC attendees compared to 
non-attendees. This effect though small may be due to the knowledge gained at DECs by 
patients of the importance of ACE inhibitors and ARBs in preventing proteinuria in 
diabetes.  
Other studies of diabetes education which examined antihypertensive medication 
use also did not show a difference between groups. A RCT of group diabetes education 
compared to usual care, showed antihypertensive medication use increased over the study 
period in both groups (Trento et al., 2002). Other studies of diabetes education did not 
measure the use of antihypertensive medications but instead examined at blood pressure 
with no difference in blood pressure between groups at the end of the study period in 
DESMOND (Davies et al., 2008) and in a meta–analysis of studies of nurse led DSME 
(Tshiananga et al., 2012). There was also an increase in ACE inhibitor prescriptions in 
those patients enrolled in a Disease Management Program for diabetes in Germany 
compared to those who were not (Berthold et al., 2011). There was an improvement in 
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meeting the diastolic blood pressure target but not systolic blood pressure. The use of 
other antihypertensive medications was not examined in this study.  
The rate of prescriptions filled for glucose monitoring strips in the 6 months after 
the index date was higher in DEC attendees than in non-attendees. The greater association 
seen with glucose monitoring strips and DEC attendance than with other outcomes is 
possibly a result of people attending a DEC being asked to monitor their blood glucose 
more often to help in the adjustment of glucose lowering therapy on future visits.  
Increases in SMBG were seen in other studies of diabetes education with variable 
of effect on A1C. A study of a DSME program showed increased SMBG in the 
intervention group at 2.88/week (95% CI 2.53-3.23) compared to the control group at 
0.62/week (95% CI 0.35-0.89, p<0.001) which was correlated with a decrease in A1C 
(Tan et al., 2011). There was an increase in testing frequency from 1.4 to 1.6 tests per day 
compared to a slight decrease in the control group in a RCT of DSME aimed at changing 
the self-care behaviours including SMBG (p=0.002) (Jones et al., 2003). In the intention 
treat analysis the reduction in A1C was not significant but was statistically significant for 
the subgroup that reached or maintained action of SMBG (p<0.003).  
The rate of receiving ophthalmology or optometry care was increased in the DEC 
attendee group compared to the non-attendee group. Diabetes education reviews the 
importance of diabetic retinopathy screening and DEC attendance may serve as a 
reminder for patients to be seen for eye care.  
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An association with diabetes education and eye care was seen in other studies. 
DEC attendance was associated with retinal screening in the following 2 years in a survey 
of people with diabetes mainly distributed through pharmacies in Ontario (Shah et al., 
2009). The rate of ophthalmological examination was 68% in the intervention group 
compared to 26% in the control group in a RCT of nurse case manager led DSME 
(Gabbay et al., 2006).  
The risk differences for the filling of prescriptions for medications between 
groups are not large, raising the question of whether the results are clinically significant. 
There was a very small difference in medication use and optometry/ophthalmology visits 
between groups at baseline with slightly higher use in the non-attendee group in the 
propensity score matched cohort. Therefore, the population is slightly biased against the 
DEC attendees at baseline which further strengthens the results of increased medication 
dispensation in DEC attendees. 
Prescriptions filled for proton pump inhibitors, prescriptions filled for 
levothyroxine, and receiving otolaryngology care were not different between DEC 
attendees and non-attendees after the index date in the propensity score matched cohort. 
These outcomes were used to demonstrate the specificity of the response to DEC 
attendance of the diabetes related outcomes. Therefore, it was expected that no 
association with DEC attendance would be seen as these medications and type of medical 
care is not related to diabetes management or its complications.  
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4.4 Difference in results of the two methods  
As expected, the different methods of analysis gave broadly similar results. The 
propensity score analysis attenuated the results seen in the logistic regression analysis. 
Both methods gave a statistically significant association of statin dispensation in the 6 
months after DEC attendance but the degree of association was stronger by the logistic 
regression that may not be as well controlled for cofounders as the propensity matched 
score.  
The secondary outcomes were also similar in the two methods of analysis. The 
association was greater with logistic regression than with propensity score matching for 
all secondary outcomes. The association was positive and statistically significant with 
both methods for all secondary outcomes except for antihypertensive medications for 
which no difference was seen between groups in the propensity score matched cohort but 
was seen in the logistic regression analysis.  
There was no statistically significant difference in prescriptions filled for proton 
pump inhibitors or otolaryngology visits in both analyses as expected as these outcomes 
are not related to diabetes management. These were used to demonstrate the specificity of 
the response to DEC attendance of the diabetes related outcomes. Prescriptions filled for 
levothyroxine in the 6 months after DEC attendance was different between groups in the 
logistic regression analysis compared to no statistically significant difference seen in the 
propensity score matched cohort. It is possible that the confounders were better controlled 
in the propensity score matched cohort than in logistic regression or it may be that the 
difference seen with logistic regression is real but the more conservative measure of 
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association of the propensity score matching attenuated the results. The large number of 
unmatched non-attendees in the logistic regression analysis may have contributed to the 
affect seen in that analysis. The propensity-matched cohort may be a better analysis of the 
effect of DEC attendance on medication dispensation.  
The two methods of analysis use different samples from the overall population. 
Logistic regression is performed on the whole cohort and is unmatched while the 
propensity matched is a sample of the population that is matched for 13 baseline variables 
and the 9 other variables for pre-index utilization. Logistic regression finds the OR by 
adjusting for the baseline and other variables of pre-index utilization while propensity 
matched adjusts the OR for propensity score. 
The two methods are also not estimating the same thing, as logistic regression 
estimates the association for the individual but propensity score matching estimates the 
association for the population. The logistic regression model estimates the conditional or 
adjusted average with the OR estimating the average change for an individual e.g. 
changing a person from not being on a statin to being on a statin. The propensity score 
matched method estimates the marginal or population average with the risk difference 
estimating the average risk of change for the population e.g. changing the whole 
population from not being on a statin to being on a statin. If the outcome studied was 
continuous, the two analyses would give the same result. However, the outcome is a 
dichotomous outcome, so the two estimations are not the same, and the population 
average usually is slightly reduced in magnitude compared to the individual average. The 
two estimates will approach each other for dichotomous outcomes that are very rare. But 
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this study uses very common outcomes as about 70% of the population were on a statin so 
the results of the two methods will be more divergent from each other as is seen.  
4.5 Strengths and Limitations  
There are many strengths associated with this study over previous studies. This 
study shows the effectiveness DSME provided through DECs in real world conditions in 
a population by using the databases of the Ministry of Health and Long Term Care. RCTs 
show the efficacy of diabetes education only in selected individuals with a specific 
curriculum in an experimental setting. Because the study used population-based data, the 
sample size is much larger than experimental studies, and there is no selection bias, loss 
to follow up or missing data. The use of population databases insures inclusion of all 
areas of the population including rural and ethnic minorities that may be missed in 
smaller studies of selected populations. As it was performed in Canada with universal 
health coverage including drug benefits covered by the ODB to those 65 years and older, 
there are no financial barriers to care as would be seen in other jurisdictions. Also it is 
unlikely people would have access to these services that are not captured in the databases. 
There are limitations associated with this study. As with all observational cohort 
studies, unmeasured and unknown confounders may be present. Although statistical 
techniques were used to adjust for these confounders, they cannot adjust for all possible 
confounders and unobserved variables and this problem cannot be eliminated in an 
observational study no matter which analysis method is used.  It is non-experimental. 
Sampling and measurement errors can affect the results. As it only uses administrative 
data there are issues with data validity. Potentially useful data is also missing as it is not 
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captured by these databases. The generalizability is limited to the over 65 population as 
prescription data is not available for younger patients. 
As this is an observational study the general limitations of all observational 
studies apply. Since it is non-experimental, sampling and measurement errors can affect 
the results. This study examines DEC attendance and quality of care outcomes but 
confounding by other explanations can limit inferences on causality. Although statistical 
techniques were used to adjust for these confounders, they cannot adjust for all possible 
confounders or unobserved variables and this problem cannot be eliminated in an 
observational study no matter which analysis method is used.  
The cohort of patients was linked through large health care databases of the 
Ontario Ministry of Health and Long Term Care permitting measurement of many 
demographic and clinical predictor variables. However, other potentially important 
demographic factors that might be associated medication and health care utilization after 
DEC attendance could not be measured from population-level data, such as health 
literacy, education level, and language proficiency. Other immeasurable or unknown 
confounders may exist in the relationship between DEC attendance and medication use, 
such as patients who are more health conscious or more motivated may be more likely to 
attend diabetes education and to perform self-care activities, including using the 
recommended medication, glucose monitoring and attending eye care. These are 
limitations of an observational cohort study and would not be present in an interventional 
trail such as a RCT. 
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The database could only be used to tell whether prescriptions were filled, not if 
they were used appropriately or used at all. It also cannot measure patients who were 
appropriately offered a prescription and refused it or took the prescription and did not fill 
it. The outcome of prescriptions filled for a medication does not equate as medication 
compliance as many filled prescriptions may go unused from non-compliance. It also 
does not capture those who could not tolerate the medication and discontinued it. 
Unfortunately only information for medications in the elderly is available through ODP, 
as only medication costs for those 65 years of age and older or of low income status is 
covered by the program. Therefore the ability to apply these results to the general adult 
population is uncertain.  
The appropriateness of medication use also cannot be assessed with administrative 
data. It is assumed that most seniors with diabetes would require statins, glucose lowering 
medications, and antihypertensive medications based on risk factor prevalence in this 
population. However, since no data is present on lipid levels, glycemic control, or blood 
pressure, the difference might also reflect different needs and appropriateness rather than 
quality of care improvements related to DEC attendance. The indications for treatment 
are also not available. Patients who filled a prescription for a beta-blocker for angina or 
an ACE inhibitor for proteinuria would both be classified as receiving antihypertensive 
treatment.  
The influence of the variability between the curricula of diabetes education 
programs could not be evaluated as this data were not available.  The variability may not 
be significant as there is a Standards Recognition Program for diabetes education that has 
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been developed by the Canadian Diabetes Association and each program must adhere to 
government-mandated standards on curriculum, staffing and access of the Ontario 
Ministry of Health and Long Term Care. This study looked at the effect of attendance at 
formal DSME programs but other sources of education such as delivered by an individual 
nurse working with a primary care physician, or by a pharmacist are not captured by this 
study. DEC attendance is known for only one year, with no data in the preceding years 
from which the effect may still be present. DEC attendance was defined as at least one 
visit to the DEC. If patients attended the DEC multiple times this information was not 
captured in this study and therefore the effect multiple visits may have had on the 
outcomes is unknown. Despite this limitation the results were still significant. 
This study relied on administrative data that was collected for reasons other than 
research, which may lead to misclassification and compromise validity.  The ODD has a 
sensitivity of 86% and a specificity of 97% with a positive predictive value of 80% (Hux 
et al., 2002) so only a small proportion may be misclassified.  DINs have been shown to 
have good prediction comorbidity in terms of health care costs and visits over the next 
year but are not the best comorbidity score to predict mortality (Perkins et al., 2004).  
Reasons for hospital and emergency room visits may be misclassified or entered as 
another presenting complaint when hypoglycaemia, hyperglycemia, coronary or 
cerebrovascular disease may also be present. Visits to specialists and primary care 
physicians are based on fee for service billing and will miss physician visits to physicians 
paid by alternative funding plans. Diabetes specialist care is extracted from the OHIP 
database as visits to an endocrinologist or internist but visits to these specialists may be 
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for other health issues unrelated to diabetes. Also, other physicians such as primary care 
physicians who focus on diabetes and provide specialized diabetes care would be missed.  
As this study uses administrative data only, much clinical information is missing. 
As the ODD does not distinguish between types of diabetes we could not compare 
medication dispensation and healthcare utilization between type 1 and type 2 diabetes, but 
in this age group assume it is a majority of type 2 diabetes. Unfortunately, as laboratory 
data is not linked electronically in Ontario, we have no data on if the metabolic targets are 
reached in this study population or if an effect is seen with DEC attendance. Although we 
were able to capture health care utilization and coronary and cerebrovascular disease we 
were not able to capture whether blood pressure targets were met. We could measure 
receiving eye care but not incidence of retinopathy.  
As prescription data is only available for the population aged 65 and older, the 
generalizability of this study is unknown in the younger population. This study was 
conducted in Ontario. However, the practice of diabetes educators across Canada is 
similar due to the guidelines set out by the Canadian Diabetes Association and likely 
similar to other countries. Therefore, these results are likely generalizable to areas outside 
Ontario. The short follow up period of this study also limits generalizability as it shows 
association in short term only. The change seen in the 6 months and 1 year after DEC 
attendance does not mean the effect will still be present in 5 years.  
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4.6 Conclusions 
Patients in routine clinical care who attended DECs had a statistically significant 
greater filling of prescriptions for cardiovascular risk reduction, prescriptions for diabetes 
treatments, and visits for retinopathy screening than those who did not attend. DECs 
educate attendees on the self-management of diabetes and its complications which 
includes the importance of lipid management, glycemic and blood pressure control, and 
retinopathy screening. Those patients aware of the necessity of medications and 
retinopathy screening for the management of diabetes and its complications are more 
likely to accept or seek a prescription or appointment for eye care which could lead to an 
increase in drug dispensation and ophthalmology/optometry visits in DEC attendees.  
This study supports that DECs improve medication dispensation and retinopathy 
screening in the elderly which lends support to the importance of DECs as a part of 
complete diabetes care and the funding of DECs as an important part of Ontario Diabetes 
Strategy. More research is required to assess if the improvements in medication 
dispensation and retinopathy screening seen leads to improvements in glycemic and 
metabolic control, quality of life, and reduction in diabetes related complications and 
mortality. 
The study examined the real world effect of DSME on improving the quality of 
care through prescription drug dispensation and retinopathy screening in the elderly in 
Ontario at a population level in a longitudinal cohort. By logistic regression, DEC 
attendance was associated with filling prescriptions for statins in the 6 months following 
attendance. DEC attendance was also associated with the dispensation of glucose 
lowering medications, antihypertensive medications, ACE inhibitors/ARBs, and glucose 
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monitoring strips in the six months following attendance and utilization of 
ophthalmology/optometry in the one year following attendance.  The propensity score 
matched analysis also showed an association of DEC attendance with dispensation of 
these medications except antihypertensive medications in the 6 months following 
attendance and utilization of ophthalmology/ optometry in the year following attendance. 
Although the propensity matched cohort attenuated the results seen with logistic 
regression, it may provide a better controlled analysis as all of the outcomes used to 
demonstrate the specificity of the response to DEC attendance of the diabetes related 
outcomes were not statistically significant. These findings corroborate that the benefits of 
DSME found in randomized trials, in carefully selected patients under experimental 
conditions, can be generalized to routine clinical care at a population level. 
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Appendix  
Cohort Dataset Creation Plan 
Name and Number of Study:  
 
Diabetes Education Center Attendance and effect 
on medication utilization in the elderly in Ontario # 
251.261 
Contacts Baiju Shah (supervisor), Cathy Murray (student) 
PIA Approved? Yes 
DCP update history V1 
Short Description of Research Question 
1. To determine if diabetes education centre 
attendance is associated with changes in 
the rates of statin utilization in the over 65 
population in routine clinical care in 
Ontario.    
2. To determine if diabetes education centre 
attendance is associated with blood glucose 
monitoring, hypoglycemic and 
antihypertensive medication utilization and 
retinopathy screening in the over 65 
population in routine clinical care in Ontario. 
List of Datasets Used DEC database, ODB, RPDB, OHIP, ODD 
Defining the Cohort 
Index Event In ODD with diagdate on or before Jan 1, 2005 
Alive until Dec 31, 2007  
Age 65 or greater on or before Jan 1, 2005 
Exclusions 
(In order) 
No valid Ontario postal code 
 
Variable Definitions 
Main Exposure 
or Risk Factor 
Index date 
Diabetes education center attendance in 2006 
 
For subjects who attended a DEC, index date = earliest date of attendance 
For subjects who did not attend a DEC, index date = randomly assigned 
following the same distribution of index dates as seen in attendees. 
Baseline 
Characteristics 
1) Age at index date 
2) Gender 
3) LHIN of residence at index date 
4) Low income flag in ODB – based on all prescriptions from Jan2005 to index 
date 
5) Duration of diabetes at index date: (identified via ODD) 
       -Diagnosis 1 to <2 years  
                         2 to <5 years 
                         ≥ 5 years    
  
 
96 
 
 
 
6) Comorbidity –number of unique DINs in the 1 year prior to index date 
7) Healthcare utilization =number of visits to a primary care physician one year 
prior to index date: from OHIP, where the physician’s main specialty in 
IPDB = “GP/FP” or “F.P/EMERGENCY MEDICINE” or “COMMUNITY 
MEDICINE”; location = office, LTC or home with %ohip_location. Only one 
claim per physician per day. 
0 visits 
1-2 visits 
3-6 visits 
7-12 visits 
≥13 visits 
8) Diabetes specialist care- at least one visit in the year prior to index date 
where the physician’s mainspecialty in IPDB = “internal medicine” or 
“endocrinology” and location=”office” “LTC” or “home” with %ohiplocation 
9) Cardiology- at least one visit in the year prior to index date where the 
physician’s mainspecialty in IPDB = “cardiology” and location=”office” 
“LTC” or “home” with %ohiplocation  
10)Nephrology- at least one visit in the year prior to index date where the 
physician’s mainspecialty in IPDB = “nephrology” and location=”office” 
“LTC” or “home” with %ohiplocation 
11)hypoglycemia or hyperglycemia = hospital admission/ER visit for 
hypoglycemia or hyperglycemia on year prior to index date (see below) 
12) hospital admission = number of days in hospital during the one year prior 
to index date. (Do not double-count overlapping hospital admissions in the 
DAD.) Log transform days+1. 
13) History of previous coronary and cerebrovascular disease in the 5 years 
before index date (see below) 
Other variables 1) prescriptions filled for statins in the 6 months before index date 
2)  prescriptions filled for blood glucose monitoring strips in the  6 months  
before index date 
3) prescriptions filled for antihypertensive medications in the 6 months before 
index date 
4) prescriptions filled for ACEIs/ARBs in the 6 months before index date 
5) prescriptions filled for glucose lowering medications in the 6 months before 
index date 
6) Prescriptions filled for proton pump inhibitors in the 6 months before index 
date 
7) prescriptions filled for levothyroxine in the 6 months before index date 
8) visits to ophthalmology or optometry in the 1 year before index date 
9) visits to ENT in the 1 year before index date 
Outcome 
Definitions 
Primary outcome 
prescriptions filled for statins in the 6 months after  index date 
 
Secondary outcomes 
1) prescriptions filled for blood glucose monitoring strips in the 6 months after 
index date  
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2) prescriptions filled for antihypertensive medications in the 6 months after 
index date 
3) prescriptions filled for ACEIs/ARBs in the 6 months after index date 
4) prescriptions filled for glucose lowering medications in the 6 months after 
index date  
5) Prescriptions filled for PPIs in the 6 months after index date 
6) prescriptions filled for levothyroxine in the 6 months after index date 
7) visits to ophthalmology or optometry in the 1 year after index date 
8) visits to ENT in the 1 year after index date 
Codes 
Hypo/hyperglycemia ICD-10 codes of interest are: E100, E101, E1063, E110, E111, E1163, 
E130, E131, E1363, E140, E141, E1463, E15, E160, E161, E162 
CIHI record with these ICD-10 codes for dx10codes with accompanying 
dxtype = admitdx 
NACRS record in FY 2005: these ICD-10 codes for dx10code with 
accompanying dxprex = R and triage ≤ 4 and visittype ≠ 3  
NACRS record in FY 2006 or 2007: these ICD-10 codes for visitreason 
and triage ≤ 4 and visittype ≠ 3 
Previous coronary/ 
cerebrovascular 
disease 
 -Acute myocardial infarction: dxcode 410 or dx10code I21 (dxtype=all) 
 -Stroke: dxcodes 431, 433, 434, 436 or dx10codes I61, I63, I64, G450 to 
G453 (dxtype=all) 
 -History of coronary revascularization: CCP codes 48.02, 48.03, 48.09 or 
incodes 1IJ50, 1IJ57, 1IJ76, 1IJ80 
Statins subclnam="ANTILIPEMIC: STATINS" or "CALCIUM BLOCKERS 
ANTILIPEMIC COMBINATIONS" 
Blood glucose 
monitoring strips 
drugname = ’DIAGNOSTIC AGENT – DIABETES’ and routeadm =: 
’STRIP’ 
Antihypertensive 
medications 
drugname in:  
acebutolol eprosartan nifedipine 
aliskiren felodipine oxprenolol 
amiloride fosinopril perindopril 
amlodipine guanethidine phenoxybenzamine 
atenolol hydralazine pindolol 
benazepril hydrochlorothiazide prazosin 
bendroflumethiazide indapamide propranolol 
bisoprolol irbesartan quinapril 
candesartan isradipine ramipril 
captopril labetalol reserpine 
carvedilol lisinopril spironolactone 
chlorothiazide losartan telmisartan 
chlorthalidone methyclothiazide terazosin 
cilazapril methyldopa timolol 
clonidine metoprolol trandolapril 
debrisoquine minoxidil triamterene 
diltiazem nadolol valsartan 
doxazosin nicardipine verapamil 
enalapril   
Include only tablet, capsule or kit forms of these drugs, not IV, ophthalmic, 
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topical, etc. 
ACEIs/ARBs subclnam = “ACE INHIBITORS” or “ACE INHIBITORS COMBINATION” 
or “ANGIOTENSIN II ANTAGONIST” or “ANGIOTENSIN II 
COMBINATION” 
Glucose lowering 
medications 
drugname in: (‘INSULIN’ ‘ACARBOSE’ ‘ACETOHEXAMIDE’ 
‘CHLORPROPAMIDE’ ‘GLICLAZIDE’ ‘GLIMEPIRIDE’ ‘GLIPIZIDE’ 
‘GLYBURIDE’ ‘METFORMIN’ ‘NATEGLINIDE’ ‘PIOGLITAZONE’ 
‘REPAGLINIDE’ ‘ROSIGLITAZONE’ ‘SITAGLIPTIN’ ‘TOLBUTAMIDE’) 
Proton pump 
inhibitors 
subclnam="PROTON PUMP INHIBITORS" 
Levothyroxine drugname =: “LEVOTHYROXINE” 
Ophthalmology or 
optometry 
OHIP feecodes = A233 to A240, C233 to C236, V401, V402, V404 to 
V409, V450, V451 
OHIP feecodes = K065, K066 where spec=23 
NOTE need to include spec=all in %getohip to include optometrists 
ENT At least one visit where the physician’s mainspecialty in IPDB = 
“OTOLARYNGOLOGY” and location=”office” “LTC” or “phone” with 
%ohiplocation 
Outline of Analysis Plan 
Compare baseline characteristics of DEC attendees and non attendees (with p-values and 
standard differences). Please run %dinexplore on all DIN lists. 
 
Logistic regression 
Compare the number of prescription filled for statins in the 6 months after index date using 
logistic regression adjusting for pre-index utilization of statins and all 13 baseline variables.  
 
Repeat the above analysis for antihypertensive medications, ACIs/ARBs, glucose-lowering 
medications, blood glucose monitoring supplies, proton pump inhibitors and levothyroxine at 6 
months, and ophthalmology/optometry and ENT at 1 year post index date. In each case, adjust 
for pre-index utilization for that category only.  
 
Matching using Propensity score  
Construct a propensity score for DEC utilization, using the following predictor variables: the 13 
baseline variables, and the 9 “other variables” (pre-index utilization). Verify balance of covariates 
between PS quintiles; add interaction or nonlinear terms as needed to achieve balance. Greedy 
match DEC attendees and non-attendees on the logit of the PS, using calipers with a width of 0.6 
x the pooled standard deviation. Compare the proportion of people with prescriptions filled for 
statins in the 6 months after index date using McNemar’s test.  
 
Repeat the above analysis for all secondary outcomes. 
 
